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STEM CELL TOURISM:  
THE CHALLENGE AND PROMISE OF INTERNATIONAL REGULATION OF  
EMBRYONIC STEM CELL-BASED THERAPIES 
Lesley N. DeRenzo 
Most cells in the human body are committed to fulfilling a single 
function. In contrast, embryonic stem cells have the ability to become over 
200 distinct cell types. Because of this distinctive characteristic, embryonic 
stem cells hold vast promise to treat a variety of diseases and disorders. 
Nevertheless, scientific experts concede that substantial advances in basic 
biology and clinical technique are essential before embryonic stem cells are 
readily available for clinical use. Despite the lack of safety and efficacy 
testing in humans, there are clinics around the world charging patients 
thousands of dollars for embryonic stem cell-based therapy. As a result, 
scientists have reported instances of patients suffering adverse outcomes 
after receiving unregulated stem cell-based therapies. Recognizing the 
global nature of science and medicine, this Note explores various solutions 
the United Nations can take to regulate the use of embryonic stem cells in 
clinical practice. 
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I. INTRODUCTION 
Stem cell-based therapies have existed since 1968 when clinicians 
performed the first bone marrow transplantation.1 Thirty years later, Dr. 
James A. Thomson, Director of Regenerative Biology for the Morgridge 
Institute for Research, derived the first human embryonic stem cell (hESC) 
  
 1 Fritz H. Bach et al., Bone-Marrow Transplantation in a Patient with the Wiskott-Aldrich 
Syndrome, 2 THE LANCET 1364 (1968) (discussing a bone marrow transplant to replace ab-
normal cells with healthy cells capable of making normal platelets, T cells, and B cells); see 
also Robert A. Good et al., Immunological Reconstitution of Sex-Linked Lymphopenic Im-
munological Deficiency, 2 THE LANCET 1366 (1968) (discussing a bone marrow transplant 
procedure for an individual with combined T-cell and B-cell immunodeficiency). A bone 
marrow transplant delivers healthy bone marrow stem cells into a patient and replaces bone 
marrow that is either not working properly or has been destroyed (i.e., ablated) by chemothe-
rapy or radiation. See U.S. Nat‘l Library of Med., Bone Marrow Transplantation, 
MEDLINEPLUS, http://www.nlm.nih.gov/medlineplus/bonemarrowtransplantation.html (last 
updated Mar. 28, 2011). 
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lines2 from left-over, pre-implantation human embryos (donated to biomed-
ical research).3 Dr. Thomson theorized that his findings could revolutionize 
medicine by generating unlimited sources of human cells for transplantation 
therapies.4 However, he cautioned that ―substantial advances in basic deve-
lopmental biology‖ were essential before hESC-based therapies would be 
ready for clinical applications.5 Indeed, scientific experts maintain that the 
only established, stem cell-based treatment in clinical practice is bone mar-
row transplantation, which incorporates the use of hematopoietic stem 
cells.6  
  
 2 Human embryonic stem cells [hESCs] are: (1) derived from human embryos, (2) can 
self-replicate indefinitely, and (3) can develop into cells and tissues of the three primary 
germ layers (i.e., endoderm, mesoderm, and ectoderm). See infra Appendix B & D; see also 
James A. Thomson et al., Embryonic Stem Cell Lines Derived from Human Blastocysts, 282 
SCI. 1145, 1145 (1998) (discussing the generation of cardiomyocytes from the first human 
embryonic stem cell lines derived from blastocysts). Furthermore, a hESC line is a popula-
tion of cells isolated from cryopreserved, pre-implantation human embryos (usually four- or 
five-days old) that can be grown indefinitely in vitro. See DEP‘T OF HEALTH AND HUMAN 
SERVICES, NAT‘L INSTITUTES OF HEALTH, STEM CELLS: SCIENTIFIC PROGRESS AND FUTURE 
RESEARCH DIRECTIONS 13 (2001), available at http://stemcells.nih.gov/staticresources/info/ 
scireport/PDFs/fullrptstem.pdf; see also infra Appendix D. 
 3 Thomson et al., supra note 2, at 1145. Individuals that had undergone in vitro fertiliza-
tion [IVF] and no longer needed their left-over embryos donated their embryos for use in Dr. 
Thomson‘s study. Id. ―[IVF] is the joining of a[n] . . . egg and . . . sperm in a [petri] dish.‖ 
U.S. Nat‘l Library of Med., In Vitro Fertilization (IVF), MEDLINEPLUS, 
http://www.nlm.nih.gov/medlineplus/ency/article/007279.htm (last updated Jan. 25, 2011) 
(stating that ―[i]n vitro means ‗outside the body[,]‘ [and] [f]ertilization means the sperm has 
attached to and entered the egg.‖). 
 4 Thomson et al., supra note 2, at 1146–47.  
 5 Id. at 1147 (emphasis added). 
 6 Bone marrow transplantations are used primarily to treat diseases of the blood system 
(e.g., treatment for leukemia and similar blood-related cancers). See, e.g., George Daley et 
al., Mapping the Road to the Clinical Translation of Stem Cells, 2 CELL STEM CELL 139, 139 
(2008). Hematopoietic (i.e., blood-forming) stem cells are extracted from bone marrow and 
are used to replace blood cells destroyed from high doses of chemotherapy. See, e.g., Jos 
Domen et al., Bone Marrow (Hematopoietic) Stem Cells, in U.S. DEP‘T OF HEALTH AND 
HUMAN SERVICES, REGENERATIVE MEDICINE 22 (2006), available at http://stemcells.nih.gov/ 
staticresources/info/scireport/PDFs/Regenerative_Medicine_2006.pdf. Hematopoietic stem 
cells are different from embryonic stem cells. More specifically, embryonic stem cells can 
develop into nearly every type of cell in the body, whereas hematopoietic stem cells divide to 
form more blood-forming stem cells, or can mature into one of three types of blood cells 
(i.e., white blood cells, which fight infection; red blood cells, which carry oxygen; and plate-
lets, which help the blood to clot). See generally U.S. DEP‘T OF HEALTH AND HUMAN 
SERVICES, STEM CELL BASICS (2009), available at http://stemcells.nih.gov/staticresources/ 
info/basics/SCprimer2009.pdf (a comprehensive review on the state of the science on stem 
cell research).  
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Once human cellular-based and tissue-based products7 became 
available for therapeutic applications, Congress assigned regulatory respon-
sibility of these products to the U.S. Food and Drug Administration (FDA).8 
The FDA identifies a broad spectrum of safety concerns related to hESC-
based products for use in human transplantation.9 More specifically, the 
FDA asserts that hESCs—and their derivatives—pose the risk for: (i) spon-
taneous formation of tumors after injection of hESCs into a human subject; 
(ii) migration of hESCs to a different site in the human body than what was 
originally intended; and (iii) development of immunogenicity because of the 
body‘s reaction to the foreign material expressed from the human proteins 
on the hESC product.10  
Moreover, it is essential that all left-over, pre-implantation embryos 
donated for clinical applications are screened for infectious diseases.11 Ac-
cordingly, without standardized safety screening of hESCs for infectious 
diseases, hESC-based therapies pose the risk of transmitting infectious dis-
eases such as Hepatitis B and HIV/AIDS to the recipients.12 While hESC 
research has many safety challenges, the FDA states that the goal of facili-
  
 7 FDA regulations define cellular-based and tissue-based products as ―articles containing 
or consisting of human cells or tissues that are intended for implantation, transplantation, 
infusion, or transfer into a human recipient.‖ 21 C.F.R. § 1271.3(d) (2010). 
 8 See generally 21 C.F.R. § 1271 (2010) (outlining FDA‘s good tissue practice require-
ments).  
Of FDA‘s many responsibilities for human health and security, the FDA is responsible for 
assuring the safety, efficacy, and security of biological products. What Does FDA Do?, FOOD 
& DRUG ADMIN., http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194877.htm (last 
updated Dec. 17, 2010). 
 9 Donald W. Fink Jr., FDA Regulation of Stem Cell-Based Products, 324 SCI. 1662 
(2009) (presenting how the FDA ensures subjects enrolled in clinical studies involving stem 
cell-based products are not exposed to significant and unreasonable risk due to the FDA‘s 
review of medical and scientific information to determine whether there is sufficient safety 
assurance to permit initiation of human clinical studies); see also Dina Gould Halme & Da-
vid A. Kessler, FDA Regulation of Stem-Cell-Based Therapies, 355 NEW ENG. J. MED. 1730 
(2006) (articulating how the FDA‘s promulgated regulations regarding human cells, tissues, 
and cellular-based and tissue-based products, provide an appropriate regulatory structure for 
the wide range of stem cell-based products that may be developed to replace or repair dam-
aged tissue). 
 10 Fink Jr., supra note 9, at 1662; see also Stem Cell Science: The Foundation of Future 
Cures: Before the Subcomm. on Health, U.S. House of Representatives’ Comm. on Energy 
and Commerce, 110th Cong. (2008) (statement of Dr. Elias A. Zerhouni, Dir. of the Nat‘l 
Institutes of Health, U.S. Dep‘t of Health and Human Services). 
 11 See 21 C.F.R. §§ 1270.21, 1271.75(a)(1)(i)–(v), 1271.85(a)(1)–(5) (2010). 
 12 In the United States, any human tissue intended for transplantation must be tested for 
the following communicable viruses: (1) HIV, (2) Hepatitis B, and (3) Hepatitis C. 21 C.F.R. 
§ 1270.21(a)(1)–(4) (2010); see also discussion infra Part III(A) (discussing threats posed by 
the potential use of modern molecular technology to produce biological weapons and the use 
of stem cells as a critical link to both evade and produce such weapons). 
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tating the development of safe and effective hESC-based products is attain-
able.13 And, the FDA emphasizes that cooperative, interdisciplinary efforts 
are essential to ensure patient safety.14  
Despite well-documented safety risks, there are clinics throughout 
the world, and outside of the FDA‘s jurisdiction, offering unregulated 
hESC-based therapies.15 Unregulated clinics increase the probability that 
vulnerable patient populations receiving these treatments will experience 
adverse outcomes.16 The risks of patients suffering harm from unsubstan-
tiated hESC-based treatments are mitigated within the United States, and in 
other developed countries, because Federal agencies actively regulate 
against unsafe medical practices.17 Unfortunately, at this time, there is no 
international governing body authorized to set and enforce regulations on 
the use of hESCs in medical practice.18 Thus, the burden of regulating 
hESC-based therapies is dependent on the enforcement mechanisms of indi-
vidual countries.19  
As stem cell treatments emerge as a developing area of medical 
tourism, scientific experts are becoming increasingly concerned with the 
potential adverse impacts of hESC-based treatments offered without regula-
tory oversight.20 Because of this concern, the International Society for Stem 
  
 13 Fink Jr., supra note 9, at 1663. 
 14 Id. 
 15 Daley et al., supra note 6, at 139. 
 16 See id. 
 17 Sorapap Kiatpongsan & Douglas Sipp, Commentary, Offshore Stem Cell Treatments, 
NATURE REP. STEM CELLS (Dec. 3, 2008), http://www.nature.com/stemcells/2008/0812/0812 
03/full/stemcells.2008.151.html (analyzing how the market approach to experimental medi-
cine, in which doctors and entrepreneurs exploit patient trust and take advantage of the 
dearth of cell therapy regulations in many countries, is destined to end badly unless there are 
clear and enforceable rules to regulate such behavior). 
 18 Id. 
 19 Id. 
 20 Medical tourism is defined as travel with the aim of improving one‘s health. See MILICA 
Z. BOOKMAN & KARLA R. BOOKMAN, MEDICAL TOURISM IN DEVELOPING COUNTRIES 1 
(2007); see also Eliza Barclay, Stem-Cell Experts Raise Concerns About Medical Tourism, 
373 THE LANCET 883 (2009) (investigating how stem cell therapies are emerging as a 
growing area of medical tourism, even while research is still in its early stages); Olle 
Lindvall & Insoo Hyun, Medical Innovation Versus Stem Cell Tourism, 324 SCI. 1664 (2009) 
(―Stem cell tourism is criticized on grounds of consumer fraud, blatant lack of scientific 
justification, and patient safety‖ and the ―conditions under which ‗unproven‘ therapies may 
be offered to patients outside of regular clinical trials‖). The World Health Organization 
[WHO] identifies medical tourism as trending upward. BOOKMAN & BOOKMAN, supra note 
20, at 2 (citing David Woodward et al., Globalization, Global Public Goods and Health, in 
WHO, TRADE IN HEALTH SERVICES: GLOBAL, REGIONAL AND COUNTRY PERSPECTIVES 3, 7 
(2002). Further, a 2008 survey of health care consumers found that the frequency of patients 
traveling abroad to obtain health care is increasing. DELOITTE CENTER FOR HEALTH 
SOLUTIONS, DELOITTE, 2008 SURVEY OF HEALTH CARE CONSUMERS (2008), available at 
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Cell Research (ISSCR) issued guidelines targeting ―stem cell tourism.‖21 
The ISSCR‘s guidelines highlight the need for well-designed clinical trials 
as an essential element for administering any proposed hESC-based ―thera-
py.‖22 While the ISSCR acknowledges a place for investigator-led medical 
innovation, it does so with the caveat that such interventions must be con-
ducted in line with the ethical obligation to do no harm.23 
Although the guidelines advocate for an international framework, 
they carry no legal force.24 Moreover, despite the efforts of a well-
intentioned international professional society, the guidelines are easily ig-
nored by unregulated clinics.25  
Therefore, Part II of this Note examines the promise of hESC-based 
therapies and highlights the challenges, or potential dangers, of stem cell 
tourism without an international regulatory framework. Part III explores a 
range of effective solutions to combat administering unsafe hESC-based 
therapies. Specifically, this includes the analysis and application of: (i) a 
binding U.N. Security Council (Security Council) Resolution to effectuate 
immediate action in the interest of national security and public health; (ii) a 
  
http://www.deloitte.com/assets/DcomUnitedStates/Local%20Assets/Documents/us_chs_Con
sumerSurveyExecutiveSummary_200208.pdf (highlighting that patients traveling to a new 
location for the purpose of obtaining quality health care at a lower price is becoming more 
prevalent and will likely continue as an emerging trend in accessing health care). 
 21 See INT‘L SOC‘Y FOR STEM CELL RES. [ISSCR], Guidelines for the Clinical Translation 
of Stem Cells (2008), available at http://www.isscr.org/clinical_trans/pdfs/ISSCRGL 
ClinicalTrans.pdf (presenting the international guidelines defining scientific, clinical, regula-
tory, ethical, and societal issues that must be addressed to ensure that basic stem cell research 
is responsibly transitioned into appropriate clinical applications for treating patients). ISSCR 
is ―an independent, nonprofit organization established to promote and foster the exchange 
and dissemination of information and ideas relating to stem cells, to encourage the general 
field of research involving stem cells and to promote professional and public education in all 
areas of stem cell research and application.‖ Mission Statement, ISSCR, http://www.isscr.org 
/mission/index.htm (last updated Oct. 2, 2003). ISSCR members agree to abide by the 
ISSCR‘s professional standards when conducting human embryonic stem cell research. Join 
ISSCR, ISSCR, http://www.isscr.org/membership/index.htm (last updated Nov. 16, 2010). 
 22 Guidelines for the Clinical Translation of Stem Cells, supra note 21. ―[C]linical trials. . . 
are generally considered to be biomedical or health-related research studies in human beings 
that follow a pre-defined protocol.‖ Understanding Clinical Trials, CLINICALTRIALS.GOV, 
http://clinicaltrials.gov/ct2/info/understand (last updated Sept. 20, 2007). 
 23 Kiatpongsan & Sipp, supra note 17. 
 24 Id. 
 25 See id. The most notorious example of clinicians and physicians disregarding medical 
guidelines in relation to human subjects research is demonstrated by the heinous acts carried 
out by Nazi doctors during World War II despite German regulations prohibiting such con-
duct. See, e.g., Michael A. Grodin, Historical Origins of the Nuremburg Code, in THE NAZI 
DOCTORS AND THE NUREMBERG CODE: HUMAN RIGHTS IN HUMAN EXPERIMENTATION 121, 
130–31 (George J. Annas & Michael A. Grodin eds., 1992) (citing 11 Reichs-
Gesundheitsblatt 174–75 (1931)). 
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resolution outside of the purview of biomedical regulations in which the 
World Health Organization (WHO) could issue a non-binding resolution; 
and (iii) model treaties and the codification of key portions of the ISSCR 
guidelines into the form of a draft treaty. 
 
II. HESC THERAPIES—INSPIRED BY THE PROMISE, RESPECTFUL OF THE 
CHALLENGE, YET NAVIGATING WITHOUT A REGULATORY ROAD MAP 
Human embryonic stem cells hold vast potential to treat a variety of 
diseases and disorders.26 However, scientific experts concede that substan-
tial advances in basic biology and clinical technique are critical before 
hESCs are readily available for use in clinical applications.27 Despite the 
lack of safety and efficacy testing in humans, there are clinics around the 
world charging patients thousands of dollars for embryonic stem cell-based 
therapy.28  
As a result, patients lured by the promise of novel stem cell treat-
ment have suffered adverse outcomes from unregulated therapies.29 Many 
stem cell scientists agree that there is a need for systemic international regu-
lation and oversight of hESC-based therapeutic treatments offered at various 
clinics around the world.30 
  
 26 See infra Appendix C for an illustration of the potential of stem cell-based research; see 
also discussion infra Part II(A) (discussing the promise of hESC-based research to allow for 
an understanding of human development and cell specialization, thereby maximizing the 
likelihood for the development of new therapies and treatments for human disease).  
 27 Stephen Pincock, Warning Against Stem Cell Tourism, ABC SCI. ONLINE (June 22, 
2007), http://www.abc.net.au/science/news/stories/2007/1958206.htm (discussing the poten-
tially grave risks of traveling internationally in search of untested stem cell treatments); see 
also discussion infra Part II(A) (highlighting that there are several major hurdles to over-
come before hESCs are available for clinical application, including: (1) generating large and 
defined populations of the desired hESCs, (2) promoting the survival of grafted hESC-
derived cells after implantation, and (3) avoiding the formation of tumors or vigorous im-
mune reactions caused by hESC-based therapy). 
 28 Online Briefing & Rapid Roundup: New Concern over Stem Cell Tourism, AUSTL. SCI. 
MEDIA CTR. (Oct. 17, 2008), http://www.aussmc.org/2008/10/rapid-roundup-new-concern-
over-stem-cell-tourism-experts-respond/ (forum where experts discuss the danger of adminis-
tering unproven hESC treatments to human subjects). 
 29 See, e.g., Norra MacReady, The Murky Ethics of Stem-Cell Tourism, 10 THE LANCET 
ONCOLOGY 317 (2009) (highlighting recent cases of adverse outcomes from unproven stem 
cell treatments). 
 30 See Guidelines for the Clinical Translation of Stem Cells, supra note 21. 
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A. The Challenge and Promise of hESC-Based Therapies  
Over the past several years, scientists have made significant disco-
veries regarding the curative potential of hESCs.31 For example, in 2009, 
scientists demonstrated in mice that hESC-derived natural killer cells32 were 
better at destroying blood cancer and solid tumors (e.g., breast and prostate 
cancer) than natural killer cells derived from umbilical cord blood.33 This 
finding could promote the use of hESC-derived natural killer cells in hu-
mans for cancer therapy.34 
Studies in mice have also shown the possibility of engineering car-
diovascular tissue for transplantation in humans by inducing hESCs to be-
come heart cells.35 If successful in humans, this therapy could replace dam-
aged heart tissue caused by heart disease.36 Another study successfully 
demonstrated that hESC-derived neurons had the capability of repairing 
damage caused by a stroke in rats.37 Rats that suffered mobility restrictions 
with their paws were able to use their paws again normally after transplanta-
  
 31 See infra Appendix C for an illustration of the potential of hESC-based research. 
 32 A natural killer cell is ―[a] type of immune cell that has granules (small particles) with 
enzymes that can kill tumor cells or cells infected with a virus.‖ Definition of Natural Killer 
Cell, NAT‘L CANCER INST., http://nci.nih.gov/dictionary/?CdrID=44062 (last visited Mar. 30, 
2011). 
 33 Peter S. Woll et al., Human Embryonic Stem Cells Differentiate into a Homogeneous 
Population of Natural Killer Cells with Potent In Vivo Antitumor Activity, 113 BLOOD 6094 
(2009) (articulating that hESC-derived natural killer cells were better than umbilical cord-
derived natural killer cells at destroying cancer in a research study with mice). 
 34 Id. 
 35 Lei Yang et al., Human Cardiovascular Progenitor Cells Develop From a KDR+ Em-
bryonic-Stem-Cell-Derived Population, 453 NATURE 524 (2008) (highlighting how scientists 
verified that cardiomyocytes (i.e., heart cells) derived from embryonic stem cells expressed 
cardiac genes, conducted electrical currents, and had the ability to repair the pumping ability 
of mouse hearts damaged by induced heart attacks). 
 36 Id. 
 37 Marcel M. Daadi et al., Adherent Self-Renewable Human Embryonic Stem Cell-Derived 
Neural Stem Cell Line: Functional Engraftment in Experimental Stroke Model, 3 PLOS ONE 
1 (2008) (discussing that post-mortem tissue sections of treated rats‘ brains showed trans-
planted human neurons, derived from embryonic stem cells, grew towards the site of neuron 
loss and did not appear to generate any tumors over a two month observational period). 
Moreover, a ―[s]troke is the third leading cause of death in the U.S. and a leading cause of 
serious, long-term disability in adults. A stroke . . . occurs when blood flow to the brain is 
interrupted [causing] brain cells in the immediate area . . . to die because they [lack] the 
oxygen and nutrients they need to function.‖ Know Stroke. Know the Signs. Act in Time., 
NAT‘L INST. OF NEUROLOGICAL DISORDERS & STROKE, http://www.ninds.nih.gov/disorders/ 
stroke/knowstroke.htm (last updated May 21, 2010). 
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tion of the hESC-derived human neurons.38 Scientists hope to one day use 
this treatment in humans who suffer mobility impairments from stroke.39  
Scientists also successfully improved the motor functions of rats 
with Parkinson‘s disease by injecting the rats with hESC-derived dopami-
nergic nerve cells.40 Unfortunately, the rats developed brain cancer as a re-
sult of stem cell treatment.41 However, if scientists can learn to control the 
spontaneous cell differentiation that caused the brain cancer in the rats, 
hESCs may one day be a plausible source of dopaminergic nerve cells for 
humans suffering from Parkinson‘s disease.42  
While hESC studies demonstrate promising advancements for po-
tential therapies,43 they are not without significant scientific hurdles and 
potential risks.44 For example, several studies have shown that hESC-based 
  
 38 Daadi et al., supra note 37. 
 39 See Guidelines for the Clinical Translation of Stem Cells, supra note 21. 
 40 Neeta S. Roy et al., Functional Engraftment of Human ES Cell-Derived Dopaminergic 
Neurons Enriched by Coculture with Telomerase-Immortalized Midbrain Astrocytes, 12 
NATURE MED. 1259 (2006) (articulating how a more efficient technique to derive dopami-
nergic neurons from hESCs allowed for the neurons to engraft into the brains of parkinsonian 
rats and significantly improve motor function). Additionally, ―[p]arkinson‘s disease . . . 
result[s] [in the] loss of dopamine-producing brain cells . . . [and] . . . [t]he four primary 
symptoms . . . are tremor . . .; rigidity . . . of the limbs and trunk; . . . slowness of movement; 
and postural instability . . . and coordination.‖ Parkinson’s Disease Information Page, NAT‘L 
INST. OF NEUROLOGICAL DISORDERS & STROKE, http://www.ninds.nih.gov/disorders/ 
parkinsons_disease/parkinsons_disease.htm (last updated Mar. 30, 2011). 
 41 Roy et al., supra note 40, at 1259. 
 42 Id. 
 43 See, e.g., Testimony of the Director of the National Institutes of Health, Dr. Elias A. 
Zerhouni, supra note 10; Gordon Keller, Embryonic Stem Cell Differentiation: Emergence of 
a New Era in Biology and Medicine, 19 GENES DEV. 1129 (2005) (articulating that hESCs 
have great potential for clinical applications to replace damaged cells and tissues in humans); 
Gretchen Vogel, Ready or Not? Human ES Cells Head Toward the Clinic, 308 SCI. 1534 
(2005) (discussing how dopamine-producing neurons derived from hESCs could provide an 
unlimited and well characterized source of cells for a variety of treatments in humans); 
Xianmin Zeng et al., An In Vitro Model of Human Dopaminergic Neurons Derived from 
Embryonic Stem Cells: MPP+ Toxicity and GDNF Neuroprotection, 31 
NEUROPSYCHOPHARMACOLOGY 2708 (2006) (discussing how ―the availability of human 
dopaminergic neurons, derived from hESCs, allows for the possibility of directly examining 
the unique features of human dopaminergic neurons with respect to their responses to phar-
macological agents as well as to environmental and chemical toxins‖); Hannes Hentz et al., 
Cell Therapy and the Safety of Embryonic Stem Cell-Derived Grafts, 25 TRENDS BIOTECH. 24 
(2006) (identifying that hESCs, or their derivatives, have an unprecedented potential to cure 
degenerative disorders); Yang et al., supra note 35; and Daadi et al., supra note 37. 
 44 See, e.g., Deepa M. Deshpande et al., Recovery From Paralysis in Adult Rats Using 
Embryonic Stem Cells, 60 ANNALS OF NEUROLOGY 32 (2006) (noting that while the hESCs 
mediated partial recovery from paralysis, hESCs have not been tested in large animals or 
humans and it is unclear whether hESCs will act the same way in a human host); Marcel 
Dihné et al., Embryonic Stem Cell-Derived Neuronally Committed Precursor Cells with 
Reduced Teratoma Formation After Transplantation into the Lesioned Adult Mouse Brain, 
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therapies can: (i) cause cancer in the host subject through spontaneous diffe-
rentiation; (ii) induce immunogenicity responses in the host subject because 
of foreign human proteins expressed from the hESCs; and (iii) migrate to 
different areas of the body other than the intended injection site.45  
According to the National Institutes of Health (NIH),46 before scien-
tists can use hESCs in transplantation therapy, hESCs must: (i) proliferate 
extensively and generate sufficient quantities of specialized cells; (ii) diffe-
rentiate into the desired cell type(s); (iii) survive in the recipient after trans-
plant; (iv) integrate into the surrounding tissue after transplantation; (v) 
function appropriately for extended periods of time; and (vi) avoid harming 
the recipient.47  
One company is on the path to demonstrate that hESC-based thera-
py in humans can be safe and efficacious. On January 23, 2009, the FDA 
granted approval for the first study of hESC-based therapy in humans pur-
suant to a 21,000-page application submitted by Geron Corporation.48 Ge-
  
24 STEM CELLS 1458 (2006) (illustrating that more than 70 percent of mice that received 
murine ESC-derived neural precursor cells develop tumors from the treatment); Rutger-Jan 
Swijnenburg et al., Clinical Hurdles for the Transplantation of Cardiomyocytes Derived 
from Human Embryonic Stem Cells: Role of Molecular Imaging, 18 CURRENT OP. IN 
BIOTECH. 38 (2006) (indicating how there remain significant hurdles before safe and success-
ful translation of hESC-based treatments will be available for clinical therapy, including the 
need to assess cells following transplantation); Jia-Yi Li et al., Critical Issues of Clinical 
Human Embryonic Stem Cell Therapy for Brain Repair, 31 TRENDS IN NEUROSCI. 146 (2008) 
(highlighting that there are several major hurdles to overcome before hESCs are available for 
clinical application, including: (1) generating large and defined populations of the desired 
hESCs, (2) promoting the survival of grafted hESC-derived cells after implantation, and (3) 
avoiding the formation of tumors or vigorous immune reactions caused by hESC-based ther-
apy); Bin Lu et al., Long-Term Safety and Function of RPE from Human Embryonic Stem 
Cells in Preclinical Models of Macular Degeneration, 27 STEM CELLS 2126 (2009) (reiterat-
ing that assessments of safety and efficacy are crucial before human hESC-based therapies 
can move into the clinic); Hannes Hentze et al., Teratoma Formation by Human Embryonic 
Stem Cells: Evaluation of Essential Parameters for Future Safety Studies, 2 STEM CELL 
RES.198 (2009) (discussing that because transplantation of hESCs into immune-deficient 
mice will result in uncontrolled cell-differentiation, standard techniques for the administra-
tion of hESC-derived cells are crucial to establishing the use of hESCs in therapeutic applica-
tions in humans); and Roy et al., supra note 40. 
 45 See sources cited supra note 44. 
 46 The National Institutes of Health [NIH] is the primary Federal agency responsible for 
conducting and supporting medical research and supports over 300,000 extramural scientists 
and research personnel at more than 3,000 institutions nationwide. About NIH, NIH, 
http://www.nih.gov/about/index.html (last updated Oct. 27, 2010). 
 47 Testimony of the Director of the National Institutes of Health, Dr. Elias A. Zerhouni, 
supra note 10, at 2 (emphasis added); see also sources cited supra note 44. 
 48 Geron Receives FDA Clearance to Begin World’s First Human Clinical Trial of Em-
bryonic Stem Cell-Based Therapy, GERON CORP. (Jan. 23, 2009), http://www.geron.com/ 
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ron‘s application described twenty-four separate animal studies that demon-
strated the effective and safe use of hESC-derived treatments for spinal cord 
injuries in mice and rats.49 According to Geron, the animal studies provided 
data showing that after the mice and rats received hESC-derived injections, 
they regained the ability to use their hind legs and did not develop tumors 
from the treatment.50 In vitro studies further demonstrated that the animals‘ 
immune systems did not attack Geron‘s hESC-derived cells as a foreign 
tissue, minimizing the risk of immunogenicity.51  
Despite the initial approval by the FDA, the project was placed on a 
clinical hold in August 2009 based on the FDA‘s review of a non-clinical, 
animal study.52 The animal study of concern to the FDA demonstrated that a 
high frequency of animals injected with Geron‘s hESC-based product de-
veloped cysts in the injury site.53 In an effort to persuade the FDA to lift its 
clinical hold, investigators recently completed a confirmatory, preclinical 
study in rats to address the FDA‘s safety and efficacy concerns.54 The FDA 
told Geron it would review the study‘s results and make a determination as 
to whether Geron‘s proposed Phase I clinical trial55 can move forward.56 On 
July 30, 2010, the FDA lifted its clinical hold on Geron‘s proposed Phase I 
  
media/pressview.aspx?id=1148. Geron is a biopharmaceutical company based in California 
and endeavors to develop first-class treatments for cancer and chronic degenerative diseases, 
including spinal cord injury, heart failure and diabetes. See id. 
 49 Id. 
 50 Id.  
 51 Id.  
 52 Geron’s IND for Spinal Cord Injury Put on Hold, GERON CORP. (Aug. 18, 2009), 
http://www.geron.com/media/pressview.aspx?id=1187 (discussing FDA‘s decision to place a 
clinical hold on Geron‘s proposed clinical trial). A clinical hold is an order issued by the 
FDA to delay a proposed clinical investigation or to suspend an ongoing investigation for the 
development of a new drug or biological product. 21 C.F.R. § 312.42(a)(2010). 
 53 Geron and FDA Reach Agreement on Clinical Hold, GERON CORP. (Oct. 30, 2009), 
http://www.geron.com/media/pressview.aspx?style=print&id=1195 (discussing Geron‘s 
agreement with FDA to submit additional safety and efficacy animal studies regarding their 
hESC-based product for spinal cord injuries). 
 54 Jason Sharp et al, Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitor 
Cell Transplants Improve Recovery after Cervical Spinal Cord Injury, 28 STEM CELLS 152 
(2010) (discussing the ability of GRNOPC1, a proprietary hESC-derived population contain-
ing myelinating oligodendrocyte progenitor cells, to restore mobility to rats with cervical 
spinal cord injuries). 
 55 Phase I studies ―evaluate how a new treatment should be given, how often, and what 
dose is safe [and] usually enrolls only a small number of patients.‖ What is a Clinical Trial?, 
NAT‘L CANCER INST., http://www.cancer.gov/clinicaltrials/learning/what-is-a-clinical-trial 
(last updated Apr. 8, 2008). 
 56 See Geron and FDA Reach Agreement on Clinical Hold, supra note 53. 
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clinical trial.57 And, in October 2010, Geron enrolled its first patient to test 
the safety and efficacy of its proposed therapeutic application for spinal 
cord injuries.58 
Unfortunately, not all countries have stringent regulations on par 
with that of the FDA to ensure the safety and efficacy of investigational, 
new therapies.59 Moreover, these deficiencies are exposed and expanded as 
individuals travel from a country with an effective regulatory regime to a 
country without effective governance, regulation, and safety practices—
hopeful to find a novel treatment not available in their own country. 
B.  Stem Cell Tourism  
Many stem cell scientists agree that there is a need for systemic in-
ternational regulation and oversight of hESC-based therapeutic treatments 
offered at various clinics around the world.60 The act of individuals travel-
ing to another country in the hope of finding a stem cell-based therapy is 
known as ―stem cell tourism.‖61 Stem cell tourism has received intense scru-
tiny based on numerous reports of charlatanry, unsubstantiated claims in 
advertisements, and adverse medical outcomes.62  
Direct-to-consumer advertising via the internet is playing a signifi-
cant role in attracting patients to seek stem cell therapies that turn out to be 
unsubstantiated.63 Privately operated clinics around the world advertise, 
  
 57 Geron to Proceed with First Human Clinical Trial of Embryonic Stem Cell-Based Ther-
apy, GERON CORP. (July 30, 2009), http://www.geron.com/media/pressview.aspx?id=1229.  
 58 Jodi Xu, Geron Enrolls First Patient in Stem-Cell Treatment Study, WALL ST. J. (Oct. 
11, 2010, 3:33 P.M. EST), http://online.wsj.com/article/SB100014240527487037941045755 
46371842991324.html. 
 59 Mark H. Wholey & Jordan D. Haller, An Introduction to the Food and Drug Adminis-
tration and How it Evaluates New Devices: Establishing Safety and Efficacy, 18 
CARDIOVASCULAR & INTERVENTIONAL RADIOLOGY 72 (1995) (discussing how FDA may 
need to compromise some of its stringent approval standards to avoid industry‘s migration to 
countries where the regulatory standards are less rigid). 
 60 Barclay, supra note 20 at 883–84; see also Bryn Nelson, Stem Cell Researchers Face 
Down Stem Cell Tourism, NATURE REPORTS STEM CELLS (June 5, 2008), http://www.nature. 
com/stemcells/2008/0806/080605/full/stemcells.2008.89.html (analyzing ―stem cell 
tourism.‖ where people travel thousands of miles and pay thousands of dollars to receive 
unregulated care); Kiatpongsan & Sipp, supra note 17; MacReady, supra note 29.  
 61 See Kiatpongsan & Sipp, supra note 17. 
 62 See id. 
 63 Darren Lau et al., Stem Cell Clinics Online: The Direct-to-Consumer Portrayal of Stem 
Cell Medicine, 3 CELL STEM CELL 591 (2008) (describing that despite the immature state of 
stem cell medicine, patients are seeking and accessing putative stem cell therapies in an 
―early market.‖). The researchers analyzed stem cell clinic websites and found that ―the 
portrayal of stem cell medicine on provider websites is optimistic and unsubstantiated by 
peer-reviewed literature.‖ Id. For an example of a clinic offering unsubstantiated stem cell 
therapies visit EmCell.com. EmCell.com is a website that makes contrary scientific claims 
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without citing to any substantiated peer-reviewed literature backing their 
practices, novel hESC-based therapies for many diseases in which conven-
tional medicine is unavailable.64 The cost of stem cell therapy averages 
$21,500 per treatment, excluding travel and accommodation.65 News reports 
from 2009 indicate that clinics in China are charging as much as $69,420 
per treatment.66 
Furthermore, there is potential for serious side effects after receiv-
ing unregulated stem cell treatments.67 For example, in an observational 
study in China, fetal brain tissue was transplanted into the lesions of more 
than 400 patients with spinal cord injury at Beijing‘s Chaoyang and West 
Hills (Xishan) hospitals.68 The visiting researchers could not find evidence 
of clinical improvement in any of the patients they observed and reported 
that several of the patients who received the treatment had developed me-
ningitis from the stem cell injections.69  
In another adverse outcome report, Israeli researchers from Sheba 
Medical Center in Tel Aviv detailed the first case of a brain tumor that de-
veloped in a male child due to an unregulated stem cell transplantation ther-
apy.70 The child and his family had sought unconventional stem cell therapy 
  
that certain stem cells can migrate to an individual‘s damaged site, engraft, proliferate, un-
dergo specialization under regulation of a new host, and substitute lost or damaged cells, thus 
restoring the impaired body functions. For additional evidence of unsubstantiated stem cell 
treatment claims, visit StemCellsChina.com. StemCellChina.com is a website providing 
specious patient testimonials about stem cell treatments. Contrary to claims by EmCell and 
StemCellsChina, the FDA asserts that hESCs—and their derivatives—pose the risk for (1) 
spontaneous formation of tumors after injection of hESCs into a human subject; (2) migra-
tion of hESCs to a different site in the human body than what was originally intended; and 
(3) development of immunogenicity because of the body‘s reaction to the foreign material 
from the human proteins expressed from the hESC product. See Fink Jr., supra note 9, at 
1662; see also Halme & Kessler, supra note 9, at 1730–31; see articles cited supra note 44.  
 64 Lau et al., supra note 63, at 591. 
 65 Id. at 592. 
 66 Barclay, supra note 20, at 884. 
 67 Bruce H. Dobkin et al., Cellular Transplants in China: Observational Study from the 
Largest Human Experiment in Chronic Spinal Cord Injury, 20 NEUROREHABILITATION & 
NEURAL REPAIR 5 (2006) (comparing available reports of patients who received preoperative 
and postoperative assessments before and up to one year after receiving biological cell-based 
implants in China). 
 68 Id. 
 69 Id. Meningitis is an inflammation of the membranes that cover the brain and spinal cord 
and is primarily caused by either a viral or bacterial infection. U.S. Nat‘l Library of Med., 
Meningitis, MEDLINEPLUS, http://www.nlm.nih.gov/medlineplus/meningitis.html (last up-
dated Mar. 25, 2011). 
 70 Ninette Amariglio et al., Donor-Derived Brain Tumor Following Neural Stem Cell 
Transplantation in an Ataxia Telangiectasia Patient, 6 PLOS MED. 221(2009) (reporting on a 
human brain tumor complicating neural stem cell therapy and advocating that further work is 
urgently needed to assess the safety of certain stem cell-based therapies).  
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offered in Russia to treat a rare neurological disorder called ataxia telangiec-
tasia, which causes severe disability.71 However, instead of the treatment 
improving the child‘s symptoms, he began to suffer from recurring head-
aches.72 When the child reported these new symptoms, researchers in Tel 
Aviv discovered that the headaches were a result of abnormal growths that 
developed in the child‘s brain and spinal cord from the stem cell-based in-
jections.73  
In another report, police in Hungary arrested four people in a raid 
conducted on a suspected, rogue stem cell clinic.74 The clinic was charging 
patients as much as $25,000 per treatment and injecting patients with ille-
gally obtained embryonic and fetal stem cells.75 The cells used at the clinic 
were derived without authorization or safety testing, posing serious risks to 
the clinic‘s patients.76 
While nothing is inherently wrong with stem cell tourism, the lack 
of standards to prove safety and efficacy of hESC-based therapies is a valid 
reason why such treatments are not available in Canada, the United States, 
and many other nations.77 Additionally, individuals suffering from debilitat-
ing conditions in which there are no conventional medical treatments are 
prime targets for clinics that market unregulated and potentially harmful 
stem cell therapies.78 According to one stem cell tourist, ―[w]hen you‘ve 
  
 71 Id. at 223. ―Ataxia telangiectasia is a primary immunodeficiency disease which affects a 
number of different organs in the body. Ataxia Telangiectasia: Fact Sheet, NAT‘L CANCER 
INST., http://www.cancer.gov/cancertopics/factsheet/risk/ataxia (last updated Jan. 6, 2006). 
An immunodeficiency disease is one that causes the immune system to break down, making 
the body susceptible to diseases. Id. There is no cure for ataxia telangiectasia.‖ Id.  
 72 Amariglio et al., supra note 70, at 223. 
 73 Id. 
 74 Stem Cell Tourism on the Rise, CELL MED. (Aug. 13, 2009), http://www.cellmedicine. 
com/tourism-caveat-emptor.asp (discussing the risks associated with stem cell tourism). 
 75 Id.  
 76 Id. 
 77 Lori P. Knowles, Stem Cell Hype and the Dangers of Stem Cell “Tourism”, STEM CELL 
NETWORK/RÉSEAU DE CELLULES SOUCHES (2008), available at http://www.stemcellnetwork. 
ca/uploads/File/whitepapers/Stem-Cell-Hype.pdf (white paper discussing the dangers of stem 
cell tourism).  
 78 See David Cyranoski, Stem-cell Therapy Faces More Scrutiny in China but Regulations 
Remain Unclear for Companies that Supply Treatments, 459 NATURE 146 (2009) (discussing 
China‘s attempt to designate all forms of stem cell therapy as ―ethically problematic,‖ ―high 
risk‖ or ―still in need of clinical verification‖); see also Patrick White, Stem Cell Therapy: 
Cure or Hoax in China? GLOBE & MAIL (Aug. 23, 2007, 9:11 AM EDT), 
http://www.theglobeandmail.com/life/article778149.ece (discussing individual patients that 
are side-stepping Canadian domestic regulations and traveling to China in hopes of a cure); 
Drew Griffin & David Fitzpatrick, U.S. Patients Try Stem Cell Therapies Abroad, CNN 
(June 2, 2009, 10:37 PM EDT), http://www.cnn.com/2009/HEALTH/06/02/stem.cell. 
therapy. 
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been in a wheel chair [sic] for 14 years, do you think it really worries [me] 
[sic] what treatment I receive?‖79  
Another stem cell tourist discovered a website by Beike Biotech-
nology in China offering stem cell treatments to restore vision in blind 
children.80 The family traveled to Hangzhou, China, with their blind, seven-
month-old daughter and paid $23,000 for their infant to have infusions of 
stem cells in her eyes.81 The doctors in China have told the parents that the 
therapy is working in their daughter.82 Despite the Chinese doctors‘ asser-
tions, Dr. Bruce Dobkin, Director of the Neurologic Rehabilitation and Re-
search Program at the University of California, Los Angeles stated that, ―it 
is extreme nonsense to think that cells can be incorporated into the complex 
nervous system and do so much, when we cannot even get cells in mice and 
rats to do very much.‖83 One Chinese scientist reasoned that, ―we think 
money is mainly behind [the treatments offered by Beike Biotechnology],‖ 
and added his concern that Beike‘s advertised therapy will create a bad rep-
utation for China‘s entire biotech industry.84 
Seriously ill individuals are often drawn to the promise of research 
or novel treatments because they believe it is a better alternative to standard 
treatment or better than no treatment at all.85 When these individuals are in 
search of a cure or treatment, it can lead to a decreased ability to properly 
  
 79 Interview by Jennifer Macey, reporter ABC, with Perry Cross, paraplegic stem cell 
tourist (Oct. 17, 2008). 
 80 Louisa Lim, Stem-Cell Therapy in China Draws Foreign Patients, NPR (Mar. 18, 
2008), http://www.npr.org/templates/story/story.php?storyId=88123868. 
 81 Id.  
 82 Id. Cf. Irana Klimanskaya et al., Derivation and Comparative Assessment of Retinal 
Pigment Epithelium from Human Embryonic Stem Cells Using Transcriptomics, 6 CLONING 
& STEM CELLS 217 (2004) (finding that with further research retinal pigment epithelium cells 
derived from hESCs might have the potential to successfully restore vision in animal models 
of age-related macular degeneration). 
 83 Lim, supra note 80; see also Klimanskaya et al., supra note 82. 
 84 Lim, supra note 80. According to one article, China‘s health ministry has ignored unau-
thorized stem cell therapies offered by hundreds of hospitals under its jurisdiction. Stem Cells 
in China: Wild East or Scientific Feast?, ECONOMIST(Jan. 14, 2010), http://www.economist. 
com/node/15268869. According to the article, Beike Biotechnology is infamous for its inter-
net claims and marketing efforts in countries across the world. Id. Beike also openly claims 
to supply stem cells to more than two dozen hospitals in China and one in Thailand for treat-
ing a myriad of conditions. Id. Despite Beike‘s claims that it treats over 6,000 patients using 
novel stem cell therapies, the company has not published any papers in internationally recog-
nized, peer-reviewed journals. Id.  
 85 CARL H. COLEMAN ET AL., THE ETHICS AND REGULATIONS OF RESEARCH WITH HUMAN 
SUBJECTS 133 (2005). Medical vulnerability is identified by five categories of vulnerability: 
(1) communicative, (2) institutional, (3) deferential, (4) medical, and (5) social. See J. Koff-
man et al., Vulnerability in Palliative Care Research: Findings from a Qualitative Study of 
Black Caribbean and White British Patients with Advanced Cancer, 35 J. MED. ETHICS 440 
(2009).  
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weigh the risks and potential benefits associated with proposed treatments.86 
This type of vulnerability increases the possibility that informed consent is 
based on misunderstanding potential benefits or motivated solely by the 
hope of finding a cure.87 This vulnerability also increases the risk that such 
participants will be exploited, because either they have unreasonable expec-
tations about the potential benefits or investigators mislead them about the 
risks in relation to any potential benefits.88 Because of the lack of interna-
tional regulation in this area, stem cell tourists who are harmed will find 
themselves lacking a clear path for legal recourse or other assistance. 
C.  International Regulation  
1.  Human subjects research 
It is the responsibility of the medical profession to insist that major 
innovations, such as the application of hESCs in clinical practice, are first 
incorporated into formal research projects.89 This is especially true given the 
World Medical Association‘s (WMA) International Code of Medical Ethics 
that states, ―[a physician shall] respect human life [and] act in the patient‘s 
best interest when providing medical care.‖90 
Notably, ―when a clinician departs in a significant way from stan-
dard or accepted practice, the innovation does not, in and of itself, constitute 
research.‖91 Nonetheless, radically new procedures of this description must 
be incorporated into formal research protocols at an early stage in order to 
determine whether the procedures are safe and effective.92  
  
 86 COLEMAN ET AL., supra note 85.  
 87 Id.  
 88 Id. Federal regulations require Institutional Review Boards [IRBs] reviewing research 
protocols to ensure that before approving any protocol, ―[r]isks to subjects are minimized‖ 
and ―[r]isks to subjects are reasonable in relation to anticipated benefits, if any.‖ 45 C.F.R. § 
46.111(a)(1-2) (2011). 
 89 REPORT OF THE NAT‘L COMM‘N FOR THE PROTECTION OF HUMAN SUBJECTS OF 
BIOMEDICAL AND BEHAVIORAL RESEARCH, THE BELMONT REPORT: ETHICAL PRINCIPLES AND 
GUIDELINES FOR THE PROTECTION OF HUMAN SUBJECTS OF RESEARCH, 44 Fed. Reg. 23192 
(Apr. 18, 1979) (codified as 45 C.F.R. § 46) [hereinafter BELMONT REPORT].  
 90 WORLD MED. ASSOC., WMA INT‘L CODE OF MED. ETHICS (2006), available at 
http://www.wma.net/en/30publications/10policies/c8/index.html. The World Medical Asso-
ciation [WMA] was founded in 1947 by twenty-seven countries and represents physicians 
around the world. About the WMA, WORLD MED. ASSOC. (2011), http://www.wma.net/en/60 
about/index.html. 
 91 BELMONT REPORT, supra note 89. 
 92 Id. (emphasis added). Regulatory approval of new therapies generally requires clear 
evidence of efficacy and safety and researchers can only obtain this evidence by well-
designed and well-conducted randomized prospective clinical trials. See RICHARD CHIN & 
BRUCE Y. LEE, PRINCIPLES AND PRACTICE OF CLINICAL TRIAL MEDICINE 7 (reprint 2008) 
(1996). 
File: DeRenzo 2 Created on: 4/2/2011 8:34:00 PM Last Printed: 5/22/2011 7:42:00 PM 
2011] STEM CELL TOURISM 893 
 
Further, clinics must not classify hESC-based therapy as an availa-
ble ―treatment‖ until hESC-based therapy is generally recognized among 
experts as a ―treatment.‖ Supporting this assertion, the U.S. Supreme Court 
held that a drug is effective if there is general recognition among experts, 
founded on substantial evidence, that the drug, in fact, produces the results 
claimed for it under prescribed conditions.93 By parallel reasoning, experi-
mental medical treatment must not be classified as an available treatment 
unless there is general recognition among experts, founded on substantial 
evidence, that the treatment, in fact, produces the results claimed under pre-
scribed conditions. Thus, it is absolutely essential that a patient has the ne-
cessary information to make an informed decision when seeking informa-
tion on whether to participate in novel ―treatments.‖ 
Having access to accurate and relevant information is essential to 
make an informed decision regarding novel medical treatment. Even one of 
the earliest known guidelines on human medical experimentation, promul-
gated in Germany in 1931, incorporated the concept of informed consent.94 
The guidelines, entitled, ―Regulations on New Therapy and Human Expe-
rimentation,‖ were issued by the German government in a Reich Circular on 
February 28, 1931.95 The guidelines stated that ―[i]nnovative therapy may 
be carried out only after the subject or his legal representative has unambi-
guously consented to the procedure in the light of relevant information pro-
vided in advance.‖96  
Germany‘s guidelines proved futile, as it was the atrocious German 
human experimentations during World War II that led to the Nuremberg 
Doctors‘ Trial of 1946 and the resulting Nuremberg Code—the first interna-
tional research guidelines.97 The very first line of the Nuremberg Code sets 
forth the essential tenant of informed consent by declaring that ―[t]he volun-
tary consent of the human subject is absolutely essential.‖98  
  
 93 U.S. v. Rutherford, 442 U.S. 544 (1979) (holding that a drug is unsafe for the terminally 
ill, as for anyone else, if its potential for inflicting death or physical injury is not offset by the 
possibility of therapeutic benefit).  
 94 THE NAZI DOCTORS AND THE NUREMBERG CODE: HUMAN RIGHTS IN HUMAN 
EXPERIMENTATION, supra note 25, at 129; see also Robert M. Sade, Publication of Unethical 
Research Studies: The Importance of Informed Consent, 75 ANNALS OF THORACIC SURGERY 
325 (2003). 
 95 THE NAZI DOCTORS AND THE NUREMBERG CODE: HUMAN RIGHTS IN HUMAN 
EXPERIMENTATION, supra note 25, at 129. 
 96 Id. at 130–31(citing 11 Reichs-Gesundheitsblatt 174–75 (1931)); see also Sade, supra 
note 94. 
 97 Sade, supra note 94, at 325. 
 98 2 TRIALS OF WAR CRIMINALS BEFORE THE NUERNBERG MILITARY TRIBUNALS UNDER 
CONTROL COUNCIL LAW NO. 10 181–82 (U.S. Gov‘t Printing Office 1946-1949) [hereinafter 
NUREMBERG CODE]. 
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Following the Nuremberg Code, the WMA approved the Declara-
tion of Helsinki in 1964.99 The Declaration of Helsinki asserts that, ―every 
medical research project involving human subjects should be preceded by 
careful assessment of predictable risks and burdens in comparison with fo-
reseeable benefits to the subject.‖100 Further, ―[t]he degree of risk taken 
should never exceed that determined by the humanitarian importance of the 
problem to be solved by the experiment.‖101  
While the Nuremberg Code and the Declaration of Helsinki set in-
ternational standards for treatment of human subjects when conducting 
medical research, neither mandate the regulation of novel biomedical inter-
ventions postured as available treatments.102 Even the Convention of Oviedo 
(Oviedo Convention), a prominent example of ethical rules related to the 
application of biology, medicine, and research in human subject experimen-
tation, does not regulate biomedical research disguised as a curative thera-
py.103  
The Oviedo Convention, a legally binding instrument signed by 
most of the European States, mandates that all ratifying States implement a 
regulatory scheme to monitor biomedical research in relation to human sub-
jects research.104 Echoing the informed consent requirements of the Nurem-
berg Code and Declaration of Helsinki, Article 5 of the Oviedo Convention 
declares that, ―[a]n [experimental medical] intervention . . . may only be 
carried out after the person concerned has given free and informed con-
sent.‖105  
Most importantly, Article 16 sets forth essential principles for the 
ethical conduct of human subjects research.106 The Oviedo Convention 
mandates that research on a person may only be undertaken if all of the fol-
lowing conditions are met: (i) [t]here is no alternative of comparable effec-
tiveness to research on humans; (ii) [t]he risks which may be incurred by 
that person are not disproportionate to the potential benefits of the research; 
  
 99 Sade, supra note 94. 
100 World Med. Assoc., Declaration of Helsinki: Ethical Principles for Medical Research 
Involving Human Subjects (June 1964), available at http://history.nih.gov/research/ 
downloads/helsinki.pdf (a statement of ethical principles that offers guidance to participants 
in medical research involving human subjects) [hereinafter Declaration of Helsinki]. 
101 NUREMBERG CODE, supra note 98, at 182. 
102 See generally Declaration of Helsinki, supra note 100; NUREMBERG CODE, supra note 
98. 
103 Convention for the Protection of Human Rights and Human Dignity of the Human 
Being with Regard to the Application of Biology and Medicine: Convention on Human 
Rights and Biomedicine, 1997, C.E.T.S. No. 164 [hereinafter Oviedo Convention]. 
104 Id.  
105 Id. art. 5 (emphasis added).  
106 Id. art. 16.  
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(iii) [t]he research project has been approved by [a] competent body after 
independent examination of its scientific merit . . .; (iv) [t]he persons under-
going research have been informed of their rights and the safeguards pre-
scribed by law for their protection; and (v) [t]he necessary consent as pro-
vided for under Article 5 has been given expressly . . . and is documented.107 
Because hESC-based therapies are not yet an acceptable curative 
treatment or therapy, any proposed intervention that uses hESC-based prod-
ucts must take place within the constraints of a carefully planned clinical 
trial.108 This will ensure the administration of hESCs falls under the provi-
sions of the Nuremburg Code, Declaration of Helsinki, and Oviedo Conven-
tion (where applicable).109 
2.  A call for international regulations—Past, present, & future 
Many clinics offering dubious hESC-based treatments are located in 
countries where regulations are less stringent regarding human subjects re-
search.110 Stem cell scientists have expressed frustration with how the multi-
jurisdictional nature of stem cell research makes it ―tremendously‖ difficult 
to regulate.111 One analysis detailed the lack of international mechanisms 
for accountability, transparency, and ethical oversight as the main reasons 
for scientific regulatory system failures.112 
Because of the regulatory difficulties, professional groups have is-
sued guidelines in relation to providing hESC-based therapies. In particular, 
the ISSCR issued guidelines entitled ―Clinical Translation of Stem Cells‖ 
that provide acceptable ways in which researchers may provide hESC-based 
  
107 Id.  
108 Regulatory approval of new therapies generally requires clear evidence of efficacy and 
safety and researchers can only obtain this evidence by well-designed and well-conducted 
randomized prospective clinical trials. See CHIN & LEE, supra note 92, at 7.  
109 Notably, there are two additional, well-established guidelines that govern the use of 
human subjects research throughout the world. They are: (1) THE COUNCIL FOR INT‘L 
ORGS. OF MED. SCIENCES, INT‘L ETHICAL GUIDELINES FOR BIOMEDICAL RESEARCH 
INVOLVING HUMAN SUBJECTS (2002) and (2) Universal Declaration on Bioethics and 
Human Rights, UNESCO Gen. Conf. Res., 33rd Sess., 33 C/Resolution 36 (Oct. 19, 
2005). 
110 Kiatpongsan & Sipp, supra note 17.  Examples of countries with less stringent regula-
tions include: China, India, Russia, and Thailand.  See id. 
111 Monya Baker, Stick to the Guidelines and Fewer Get Hurt, NATURE REPORTS STEM 
CELLS (Dec 11, 2008), http://www.nature.com/stemcells/2008/0812/081211/full/stemcells. 
2008.157.html (discussing ISSCR‘s hope that its guidelines will prompt regulators and gov-
ernments to close ―shady‖ clinics that offer unproven stem cell therapies); see also Guide-
lines for the Clinical Translation of Stem Cells, supra note 21. 
112 See, e.g., Herbert Gottweis & Robert Triendl, South Korean Policy Failure and the 
Hwang Debacle, 24 NATURE BIOTECH. 141 (2006). 
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therapies.113 The ISSCR strongly condemns clinics that promote and admi-
nister unproven uses of stem cells, or their direct derivatives, to patients 
outside of a clinical trial—particularly when patients are charged for those 
services.114 Even so, the ISSCR concedes that it will not enforce the guide-
lines or evaluate individual clinics for compliance.115 Nonetheless, the 
ISSCR is hopeful that the publication of its guidelines will push countries to 
adopt and enforce harmonized regulatory standards.116 
Another international professional society, the BIONET Expert 
Group (BIONET), warns that legal, political, social, and cultural differences 
between nations can lead to ―multiple standards and even to gaps [between] 
governance regimes.‖117 BIONET has called for a joint advisory body to 
monitor research practices internationally.118 
Although setting common standards in the biomedical field can be 
an arduous task, it is possible because international human rights law pre-
supposes that some basic principles of human rights transcend cultural di-
versity.119 Additionally, international organizations such as the ISSCR and 
BIONET provide a forum for discovering multinational standards in hESC 
research.120  
One example of collaboration in setting international scientific 
standards is the Universal Declaration on the Human Genome and Human 
Rights (Universal Declaration).121 The Universal Declaration publicized the 
immense potential of therapeutic applications related to gene therapy, but 
emphasized that any such research involving gene therapy should ―fully 
respect human dignity, freedom[,] and human rights . . .‖122 
  
113 Guidelines for the Clinical Translation of Stem Cells, supra note 21; see also Lindvall 
& Hyun, supra note 20, at 1665. 
114 Guidelines for the Clinical Translation of Stem Cells, supra note 21.  
115 Stem-Cell Society Condemns Medical Tourism, 453 NATURE 969 (2008) (announcing 
ISSCR‘s official condemnation towards clinicians offering unproven stem-cell treatments to 
vulnerable patient populations). 
116 Id. 
117 Daniel Cressey, Ethics Scrutiny Needed for Chinese-European Projects, 461 NATURE 
157 (2009). 
118 Id. 
119 Roberto Andorno, Biomedicine and International Human Rights Law: In Search of a 
Global Consensus, 80 BULL. OF THE WORLD HEALTH ORG. 959 (2002) (discussing the global 
challenges raised by biomedical advances).  
120 Id. 
121 Universal Declaration on the Human Genome and Human Rights, G.C. Res. 16, U.N. 
ESCOR, 29th Sess., 26th plen. mtg. (Nov. 11, 1997).  
122 Id. 
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The United Nations responded similarly when citizens worldwide 
learned that scientists had successfully cloned a sheep.123 Concern quickly 
spread that scientists could apply the same technique to produce genetically 
identical human beings.124 As a result, the French and German governments 
petitioned the United Nations to approve a worldwide ban on human clon-
ing.125 In response, on December 12, 2001, the U.N. General Assembly es-
tablished the Ad Hoc Committee on an International Convention Against 
the Reproductive Cloning of Human Beings.126 On March 8, 2005, the U.N. 
General Assembly adopted a non-binding resolution calling for the ban of 
all forms of human cloning contrary to human dignity.127 
Professional society guidelines and U.N. declarations have formed a 
directional point of origin to help determine the path forward in the regula-
tion of hESC-based therapies. From here, a range of effective solutions 
emerge—each helping to fulfill the promise of ever-advancing hESC-based 
therapies. Specifically, this journey includes the analysis and application of: 
(i) a binding U.N. Security Council Resolution to effectuate immediate ac-
tion in the interest of national security and public health; (ii) a resolution 
outside of the purview of biomedical regulation in which WHO could issue 
a non-binding resolution; and (iii) model treaties and the codification of key 
portions of the ISSCR guidelines into the form of a draft treaty. 
III. HESC THERAPIES—A REGULATORY ROAD MAP TO HELP 
GUIDE THE JOURNEY 
Scientific advances are dependent on collaborative, international re-
search—as science is not constrained by geographic boundaries. The inter-
national community must implement a standardized ethical and regulatory 
framework to address the emerging and complex scientific and social chal-
lenges generated by hESC-based therapies. While there are various ap-
proaches the international community could take to regulate hESC thera-
  
123 Andorno, supra note 119. The term cloning is used to describe the process of making 
duplicate biological material. Kathi E. Hanna, Cloning/Embryonic Stem Cells, NAT‘L HUM. 
GENOME RES. INST.(Apr. 2006), http://www.genome.gov/10004765. 
124 Andorno, supra note 119.  
125 Id.  
126 U.N. Ad Hoc Committee on an Int‘l Convention Against the Reproductive Cloning of 
Human Beings, U.N., http://www.un.org/law/cloning/ (last updated May 15, 2005); see also 
Erika Check, Call for Cloning Ban Splits UN, 416 NATURE 3 (2002) (discussing international 
debate regarding the U.N.‘s proposed global ban on human cloning); Nigel Williams, UN 
Stalls on Human Cloning, 14 CURRENT BIOLOGY R937 (articulating how the U.N.‘s attempt 
to come up with a resolution on the issue of human cloning was postponed due to continued 
debate amongst countries over a world-wide human cloning ban). 
127 U.N. Declaration on Human Cloning, G.A. Res. 59/280, annex, U.N. Doc. 
A/RES/59/280 (Mar. 23, 2005). 
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pies, the establishment of a formal, international standard is the critical first 
step to advance the regulation of hESCs. This section explores three differ-
ent options available for the regulation of hESC-based therapies.  
A.  Leveraging a Binding U.N. Security Council Resolution – Imme-
diate Action to Protect National Security and the Public Health 
1.  The binding resolution—Lessons from 9/11 
Under the U.N. Charter, the Security Council has primary responsi-
bility for maintaining international peace and security.128 Article 39 of the 
Charter allows the Security Council broad discretion to assess whether 
threats to peace exist, and Chapter VII provides for flexibility to decide on 
appropriate responses.129 Article 25 of the Charter obligates member States 
to comply with the binding Resolutions adopted by the Security Council 
under its Chapter VII authority.130 
On September 28, 2001, weeks after the horrific 9/11 attacks on 
America, the Security Council adopted Resolution 1373—a ―wide-ranging, 
comprehensive resolution with steps and strategies to combat international 
terrorism.‖131 In effect, Resolution 1373 converted the International Con-
vention for the Suppression of the Financing of Terrorism,132 which had not 
yet been universally ratified, into instant international law, binding on all 
192 Members of the United Nations. The Security Council then adopted 
Resolution 1377 on November 28, 2001, reaffirming Resolution 1373.133 
  
128 The U.N. Security Council has:  
[P]rimary responsibility, under the Charter for the maintenance of international 
peace and security . . . . [A] representative of each of its members must be present 
at all times at United Nations Headquarters . . . . When a complaint concerning a 
threat to peace is brought before [the Council], the Council‘s first action is usually 
to recommend to the parties to try to reach agreement by peaceful means. In some 
cases, the Council itself undertakes investigation and mediation. It may appoint 
special representatives or request the Secretary-General to do so . . . . It may set 
forth principles for a peaceful settlement. 
U.N. Security Council: Background, U.N., http://www.un.org/Docs/sc/unsc_background. 
html (last visited Mar. 26, 2011). 
129 The U.N. Charter article 39 states ―[t]he Security Council shall determine the existence 
of any threat to the peace, breach of the peace, or act of aggression and shall make recom-
mendations, or decide what measures shall be taken in accordance with Articles 41 and 42, to 
maintain or restore international peace and security.‖ 
130 U.N. Charter art. 25.  
131 S.C. Res. 1373, U.N. Doc. S/RES/1373 (Sept. 28, 2001); see also Press Release, Securi-
ty Council Adopts Wide-Ranging Anti-Terrorism Resolution; Calls for Suppressing Financ-
ing, Improving International Cooperation, U.N. Press Release SC/7158 (Sept. 28, 2001). 
132 G.A. Res. 54/109, U.N. Doc. A/RES/54/109 (Feb. 25, 2000). 
133 S.C. Res 1377, U.N. Doc. S/RES/1377 (Nov. 12, 2001). 
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Resolution 1377 tasked the States with, among other action items, promot-
ing best -practices in the areas covered by Resolution 1373, including the 
preparation of model laws.134 Because the Security Council adopted Resolu-
tion 1377 under Chapter VII of the U.N. Charter, Resolution 1377 imposes 
binding obligations (in contradistinction to voluntarily entering a treaty) on 
Member States to address the global issue of threats to peace and security 
represented by terrorism.135  
According to one scholar, the Security Council, for the first time, 
―[mandated] all [S]tates to take or to refrain from specified actions in a con-
text not limited to disciplining a particular country.‖136 The U.N. Security 
Council can only bind Member States if a determination is made by the Se-
curity Council, under Article 39, that a threat to the peace, breach of the 
peace, or act of aggression exists.137 
2.  Unregulated hESC-based therapies—A threat to peace? 
Some experts warn that the major threat of hESC research is not the 
often cited violation of ethical norms, but the possibility that stem cells will 
be used to bring physical harm to the human race.138 While some may scoff 
at the idea that this particular type of danger is possible, using biologics for 
human harm is not a new concept.139 The deployment of biological agents is 
  
134 Id. 
135 Id. 
136 Paul C. Szasz, The Security Council Starts Legislating, 96 AM. J. INT‘L L. 901 (2002) 
(discussing how, for the first time, the United Nations Security Council used its Chapter VII 
powers under the Charter with its resolution to counter the threat of terrorism). 
137 See U.N. Charter, supra note 129 and accompanying text. The structure of the U.N. 
Security Council consists of five permanent members with veto power (i.e., China, France, 
Russia, the United Kingdom, and the United States) and ten elected non-permanent members 
that serve for two-year terms. U.N. Charter arts. 23 & 27. 
138 LEO FURCHT & WILLIAM HOFFMAN, THE STEM CELL DILEMMA: BEACONS OF HOPE OR 
HARBINGERS OF DOOM? 195 (2008) (indicating that while stem cells offer the hope of creat-
ing or repairing tissues lost to age, disease, and injury—because of this very ability—they 
hold the potential to incite an international biological arms race); see also Zach W. Hall, 
Resource Review, Stem Cells and Leonardo’s Cave, 2 CELL STEM CELL 536 (discussing how 
the authors of ―The Stem Cell Dilemma: Beacons of Hope or Harbingers of Doom?‖ are 
rightly alarmed by the threats posed by the potential use of modern molecular technology to 
produce biological weapons and see stem cells as a critical link in efforts to both evade and 
produce such weapons). 
139 See Amerithrax or Anthrax Investigation, FEDERAL BUREAU OF INVESTIGATION [F.B.I.], 
http://www.fbi.gov/anthrax/amerithraxlinks.htm. ―Soon after the terrorist attacks of 9/11/01, 
letters laced with anthrax began appearing in the U.S. mail. Five Americans were killed and 
17 were sickened in what became the worst biological attacks in U.S. history.‖ Id. 
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no longer a hypothetical scenario, but a potentially life-threatening reali-
ty.140  
According to the NIH, the anthrax attacks, subsequent to 9/11, ex-
posed vulnerabilities in the United States and abroad to unconventional 
weapons employed by terrorists.141 More specifically, the use of anthrax 
demonstrated that terrorists could use deadly pathogens and biologics to 
threaten the health and safety of citizens around the world.142 Given the 
enormity of the threat of a biological attack, NIH spent over $1.7 billion in 
2009 towards biodefense research, with projections showing plans to spend 
equivalent amounts in the following years.143 
Of great concern with bioterrorism is that civilian populations vary 
significantly in their susceptibility to exposure from harmful biological 
agents—mainly due to differences in age (e.g., infants to the elderly) and 
health (e.g., immunocompromised to healthy immune systems).144 Countries 
around the world all face an uncertain, but real threat—the deliberate act of 
introducing re-emerging and emerging communicable diseases into the civi-
lian population.145 Additionally, authorities state that countries in the Mid-
dle East, South Asia, and Southeast Asia face the risk that transnational 
  
140 Reschma Agarwal et al., Biological Warfare – An Emerging Threat, J. OF THE ASS‘NS OF 
PHYSICIANS OF INDIA (2004). 
141 The Role of NIH Biomedical Research in Responding to the Threats of Chemical, Bio-
logical, Radiological and Nuclear (CBRN) Terrorism: Hearing Before the H. Comm. on 
Gov’t Reform, Subcomm. on Nat’l Sec., Emerging Threats, and Int’l Rel., 109th Cong. (2005) 
(statement of Anthony S. Fauci, M.D., Director, Nat‘l Institute of Allergy and Infectious 
Diseases, Nat‘l Institutes of Health, U.S. Dep‘t of Health and Hum. Services). 
142 Id. 
143 Research Portfolio Online Reporting Tools (RePORT), Estimates of Funding for Vari-
ous Research, Condition, and Disease Categories (RCDC), NIH, http://report.nih.gov/rcdc/ 
categories/default.aspx (last updated Feb. 14, 2011). NIH is the lead recipient of Federal 
biodefense dollars. See Crystal Franco, Billions for Biodefense: Federal Agency Biodefense 
Funding, FY2008-FY2009, 6 BIOSECURITY & BIOTERRORISM: BIODEFENSE STRATEGY, 
PRACTICE, & SCI. 131, 138 (2008) (analyzing the budgets and allocations for biodefense at 
the Departments of Health and Human Services, Homeland Security, Defense, Agriculture, 
and State and the Environmental Protection Agency and the National Science Foundation). 
144 Bioterrorism includes the use of ―living organisms, whatever their nature, or infective 
material derived from them, which are used for hostile purposes and intended to cause dis-
ease or death in man, animals and plants, and which depend for their efforts on the ability to 
multiply in the person, animal or plant attacked.‖ See, e.g., Nicholas J. Beeching et al., Bio-
logical Warfare and Bioterrorism, 324 BMJ 336, 336 (2002); Anthony S. Fauci, Bioterror-
ism: Defining a Research Agenda, 57 FOOD & DRUG L.J. 413 (2002) (analyzing the laws, 
regulations, and policies affecting FDA-regulated products). 
145 See Fauci, supra note 144, at 420. Pandemic influenza is an example of a re-emerging 
disease. Id. In 1918. pandemic influenza  killed an estimated twenty-five million people 
worldwide, including 750,000 in the United States. Id. HIV/AIDS, an example of an emerg-
ing disease, has now killed more than twenty-two million people and infected forty million 
others worldwide. Id. 
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terrorist groups can acquire biologics easily, as they have poorly secured 
biological laboratories and culture collections.146  
One al-Qaeda training manual advocates for the use of biologics in 
terrorist attacks.147 However, rudimentary lab equipment and limited access 
to lethal strains hindered al-Qaeda‘s known bioweapons efforts.148 Despite 
al-Qaeda‘s set-backs, some experts predict that a biological attack could 
occur by the end of 2013.149 Even more, a news report from 2010 acknowl-
edged the possibility that terrorist groups were selling fake pharmaceutics 
on the black-market as a profit-making venture to fund terrorist activities for 
the purpose of implementing a biological attack.150  
The field of biotechnology is emerging and proliferating before the 
full impact is understood and ―well before laws and policies are in place to 
ensure their use for peaceful purposes.‖151 As one scholar noted, ―[e]very 
major technology—metallurgy, explosives, internal combustion, aviation, 
electronics, nuclear energy—has been intensively exploited, not only for 
peaceful purpose, but also for hostile ones.‖152 
One muggy Sunday in July 1939, physicists Leo Szilard and Eugene 
Wigner paid a visit to Albert Einstein at Little Peconic Bay on Long Isl-
and, where he was spending the summer. They broke the news to Einstein 
about the recent experimental work with neutrons. They suggested it 
would be possible to use a neutron, discovered only seven years earlier, to 
start a chain reaction in the uranium nucleus. His Response? ―I never 
thought of that.‖ The man who launched a revolution in physics had not 
imagined that his famous equation of 1905, E=mc2, might be used to re-
lease massive amounts of energy in a weapon of war. Six years later to the 
day, July 16, 1945, the nuclear chain reaction that the world‘s greatest 
scientific mind had never considered was initiated at the ―Trinity‖ atomic 
bomb test site on a desert flat north-west of Alamogordo, New Mexico.
153
 
Imagine a situation in which an unsuspecting stem cell tourist is in-
jected with a communicable biological agent under the auspices of receiving 
hESC-based therapy. This innocent individual, paying upwards of $65,000 
  
146 BOB GRAHAM ET AL., THE REPORT OF THE COMMISSION ON THE PREVENTION OF WMD 
PROLIFERATION AND TERRORISM xix (2008). 
147 Joby Warrick, Officials Fear Toxic Ingredient in Botox Could Become Terrorist Tool, 
WASH. POST (Jan. 25, 2010), http://www.washingtonpost.com/wp-dyn/content/article/2010/ 
01/24/AR2010012403013.html?hpid=topnews. 
148 Id. 
149 GRAHAM ET AL., supra note 146, at xv. 
150 Warrick, supra note 147. 
151 DANIEL M. GERSTEIN, BIOTERROR IN THE 21ST CENTURY 17 (2009). 
152 Id. at 37 (citing NRC and the IOM, Globalization, Biosecurity, and the Future of the 
Life Sciences 49.). 
153 FURCHT & HOFFMAN, supra note 138, at 230. 
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for putative therapy, may not only serve as a potential human vector to 
transmit toxic biological agents, but may be unknowingly contributing to 
the financing of terrorist activities.154 And, similar to worries articulated in 
the 2010 news report, these unregulated clinics may be using funding from 
stem cell tourists to advance other forms of bioweapons.155 
While the probability of the above hypothetical situation is 
unknown, so significant are the consequences that they cannot be left to 
chance.156 Just as the world would not sit idly by as rouge scientists 
assembled the components of a nuclear weapon, the United Nations must 
act to ensure national security. As one atomic bomb historian prophetically 
asserted days leading up to the Manhattan Project, ―[t]he bomb was latent in 
nature as a genome is latent in flesh.‖157 Thus, unregulated hESC-based 
therapies offered in rogue clinics around the world may fall under the 
purview of the Security Council‘s Chapter VII authority. Furthermore, 
Security Council Resolution 1377 provides the United Nations flexibility to 
institute a standardized regulatory scheme for hESC-based therapy by 
binding Member States to ―intensify their efforts to eliminate . . . 
international terrorism.‖ 158 
 
3.  Taking a proactive stance towards hESC regulation 
 
While resolutions are typically non-binding legal instruments, the 
flexibility to impose binding resolutions can be extremely powerful in 
prompting individual States to act. For example, scholars assert that the 
international community‘s agreement to refrain from directly or indirectly 
  
154 See, e.g., Warrick, supra note 147 (purchasing pharmaceutics off the black-market may 
fund terrorist activities). 
155 See id.; Agarwal et al., supra note 140. 
156 The factors which effect the issue of biological weapons include:  
the dual use problem involving materials, equipment, and knowledge which has 
both legitimate peaceful and (illegitimate) hostile applications; the biotechnology 
revolution and related developments (e.g. synthetic biology); globalization and the 
increase in trade; the inherent weaknesses in the existing law against the use and 
development of biological weapons in the 1925 Geneva Protocol and the 1972 Bio-
logical Weapons Convention [―BWC‖]; . . . ; the threat posed by terrorists and non-
state actors and their increased interest in biological weapons; public and govern-
ment fear of biological weapons use (particularly in Western states) that may have 
an impact physically, economically, and psychologically well beyond any actual 
‗success‘ rate; renewed interest in incapacitating and disabling chemical and bio-
logical substances; and a crisis of legitimacy related to the actions and policies to 
counter the biological weapons threat. 
JEZ LITTLEWOOD, MANAGING THE BIOLOGICAL WEAPONS PROBLEM: FROM THE INDIVIDUAL TO 
THE INTERNATIONAL 4 (2006).  
157 FURCHT & HOFFMAN, supra note 138, at 224. 
158 S.C. Res. 1377, U.N. Doc. S/RES/1377 (Nov. 12, 2001). 
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financing terrorist activities was successfully implemented through policies 
in the United States and overseas.159 As a result, scholars declare that al-
Qaeda suffered financially, inhibiting the ability to conduct terrorist activi-
ties.160  
Yet, other scholars in the international community profess that the 
United Nations resolution has had only a minimalistic impact on combating 
the financing of terrorist activities.161 In particular, a report by a Security 
Council monitoring group observed that al-Qaeda has sustained considera-
ble financial resources despite international efforts to eliminate their fund-
ing.162 
One explanation for this is the possibility that terrorist financing is 
sustained by transferring funds through a corrupt organization that claims to 
have charitable, social, or cultural goals.163 This may be further bolstered by 
a Security Council Resolution that creates a humanitarian exception to 
freezing financial assets if the assets are necessary to cover basic living ex-
penses such as food, rent, mortgage, medicines, and medical treatment.164  
Similar to al-Qaeda terrorists that operate independent from any one 
foreign financial benefactor, raising their assets from legitimate and nonde-
script commercial entities, rogue stem cell clinics operate in various centers 
around the world—each with sources of revenue difficult to track and con-
trol.165 Establishing an international regulatory framework is essential to 
promoting security awareness in the life sciences community and mitigates 
the ability of terrorists to employ biological technology for less than noble 
purposes.166 
As with any proposed solution, there will be difficulties in measur-
ing its effectiveness. While there are conflicting reports about the level of 
effectiveness anti-terrorist financing campaigns have had on the reduction in 
terrorist activity, any positive effect, regardless of the size of the impact, is 
  
159 U.S. TREASURY DEP‘T, CONTRIBUTION BY THE DEP‘T OF THE TREASURY TO THE 
FINANCIAL WAR ON TERRORISM 5 (2002), available at http://www.treas.gov/press/releases/ 
reports/2002910184556291211.pdf; but see U.N. Security Council, Second Report of the 
Monitoring Group Established Pursuant to Security Council Resolution 1363 (2001) and 
Extended by Resolution 1390, 3, U.N. Doc. S/2002/1050 (Sept. 20, 2002). 
160 U.S. TREASURY DEP‘T, supra note 159. 
161 U.N. Security Council, supra note 159, at 3. 
162 Id.; but see U.S. TREASURY DEP‘T, supra note 159, at 5. 
163 JIMMY GURULÉ, UNFUNDING TERROR: THE LEGAL RESPONSE TO THE FINANCING OF 
GLOBAL TERRORISM 104 (2008). 
164 S.C. Res. 1452, ¶1, U.N. Doc. S/RES/1452 (2002) (emphasis added). 
165 Fund-Raising Methods and Procedures for Int’l Terrorist Orgs. Before the Subcomm.on 
Oversight and Investigations of the H. Comm. on Financial Services, 107th Cong. (2002) 
(testimony of Steven Emerson, Exec. Dir. for the Investigative Project). 
166 GERSTEIN, supra note 151, at 8, 139. 
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meaningful. Therefore, leveraging the authority provided in Security Coun-
cil Resolution 1377 is a critical first step to publicizing international con-
sensus on hESC-based therapies.  
However, if the Security Council is simply unable—due to lack of 
actionable information—to address this issue as one that poses a threat to 
national security, there are other necessary steps the United Nations should 
take to address the risks associated with receiving unregulated hESCs. 
B. Implementation of a Non-Binding UN Resolution – Looking For Short 
Term Direction Outside of Biomedical Regulation 
International consensus is critical to the success of mitigating the 
chance that patients will suffer an adverse outcome from putative hESC-
based therapies or that nations will experience public health threats from 
untested biologics. While the lawmaking process is often accused of failing 
to keep up with scientific advances, standardized ethical principles with-
stand the passage of time.167 Thus, the WHO must act to pass a non-binding 
resolution, at a minimum, regarding the international community‘s stan-
dards in relation to hESC-based therapies.168 The WHO‘s constitution pro-
vides it the ability ―to propose conventions, agreements and regulations, and 
make recommendations with respect to international health matters.‖169 
Thus, the WHO can act to promote a non-binding resolution that condemns 
clinics that offer unsafe hESC therapies. 
While not topically analogous, the principles embodied in the U.N. 
Resolution on Human Rights and Terrorism is a model resolution adaptable 
by the WHO to the problem of clinics offering unsubstantiated hESC-based 
therapies. Through the United Nation‘s Resolution on Human Rights and 
Terrorism, the international community has spoken clearly, and without 
ambiguity, expressing ―condemn[ation] [of] all acts, methods and practices 
  
167 Andorno, supra note 119. 
168 In 1948, the United Nations established the World Health Organization [WHO]. Histo-
ry of WHO, WHO, http://www.who.int/about/history/en/index.html. The WHO is the ―di-
recting and coordinating authority for health within the [U.N.] [and is] responsible for pro-
viding leadership on global health matters, shaping the health research agenda, setting norms 
and standards, articulating evidence-based policy options, providing technical support to 
countries and monitoring[,] and assessing health trends.‖ About WHO, WHO, 
http://www.who.int/about/en/. WHO acts ―as the directing and coordinating authority on 
international health work.‖ Const. of the WHO, art. 2(a), 62 Stat. 2679, 14 U.N.T.S. 
185. The World Health Assembly [WHA] is comprised of 193 U.N. Member States and 
makes major policy decisions regarding the WHO‘s initiatives. Countries, WHO, 
http://www.who.int/countries/en(listing WHO member states)(last visited Mar. 26, 
2011). 
169 Const. of the WHO, supra note 168, art. 2(k). 
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of terrorism in all its forms and manifestations.‖170 The international com-
munity has further called upon States to ―refrain from financing, . . . provid-
ing training for, or otherwise encouraging terrorist activities.‖171  
Both the statement of condemnation, and the call upon States to act, 
is essential for a hESC-based therapies resolution. Following the United 
Nation‘s lead in addressing terrorism, the WHO, acting in its capacity as the 
specialized health agency of the United Nations, must issue a non-binding 
resolution that (i) condemns clinics that promote or administer unproven 
uses of stem cells to patients outside of a clinical trial and (ii) calls upon 
States to close down clinics and sensor individuals that violate hESC-based 
therapy guidelines. 
While it is still too soon to know whether hESCs will offer the cures 
millions of people hope for, what is certain is that the power of biotechnol-
ogy crosses international boundaries more freely than ever.172 And, the key 
to scientific progress is based on the ―unification rather than fragmentation 
of knowledge.‖173 Thus, broader global cooperation among countries and 
their biological scientists may be the world‘s best approach to promote 
scientific progress.174 
The impact of a resolution can help increase the safety, efficacy, 
and transparency of hESC-based therapies and, in the process, reduce the 
number of rouge stem cell clinics offering unregulated therapies.175 A reso-
lution would also, in effect, increase knowledge and awareness and help 
align stem cell tourists‘ expectations with the promise of hESC-based thera-
pies.176 Thus, urging the regulation of hESC-based therapy can mean pre-
venting susceptible patients in Hungary from paying thousands of dollars 
for unregulated stem cell injections.177 Or, it could mean saving the child in 
Israel from suffering abnormal growths on his brain and spine due to irres-
ponsible and ineffective cell-based treatment.178  
If countries adopt regulations based on the WHO‘s guidance, then 
stem cell tourists can travel with additional confidence that they are pur-
suing hESC-based therapies that are regulated and, in the process, benefit 
from international cooperation in science. 
  
170 G.A. Res. 48/122, U.N. Doc. A/RES/48/122 (Dec. 20, 1993); see also G.A. Res. 49/185, 
U.N. Doc. A/RES/49/185 (Dec. 23, 1994). 
171 See G.A. Res. 51/210, ¶ 3(f)(5), U.N. Doc. A/RES/51/210 (Dec. 17, 1996). 
172 GERSTEIN, supra note 151, at 192. 
173 Id. 
174 Id. at 194 
175 See GREGORY D. KOBLENTZ, LIVING WEAPONS: BIOLOGICAL WARFARE AND 
INTERNATIONAL SECURITY 8 (2009). 
176 See GERSTEIN, supra note 151, at 143. 
177 Stem Cell Tourism on the Rise, supra note 74. 
178 Amariglio et al., supra note 70. 
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C.  Codifying the ISSCR Guidelines by Leveraging Principles from 
Model Treaties 
As previously discussed, hESC-based therapies have transcended 
the national stage into a global forum in need of international regulation.179 
And, if the U.N. Security Council does not leverage its powers under its 
binding resolution, and the WHO does not propose a non-binding resolu-
tion, there are additional steps the United Nations can take to regulate 
hESC-based therapies and mitigate the possibility of patients suffering ad-
verse health outcomes from unregulated treatments. 
1.  ISSCR guidelines 
The Task Force for the Clinical Translation of Stem Cells, a multi-
disciplinary group of stem cell researchers, clinicians, ethicists, and regula-
tory officials from 13 countries, developed the ISSCR guidelines.180 The 
ISSCR decided to take steps to prompt the international community to adopt 
uniform regulations for hESC-based therapies.181 This was largely due to 
the desire to mitigate the occurrence of adverse outcomes in vulnerable pa-
tient populations, persuaded by means of misleading advertising, to pursue 
unproven stem cell-based therapies abroad.182  
Because peer-reviewed scientific literature has not yet shown 
hESCs to be safe for transplantation into humans, the ISSCR strongly con-
demns clinics that promote and administer unproven uses of stem cells to 
patients outside of a clinical trial.183 More specifically, the ISSCR guide-
lines specify that ―all studies involving clinical applications of stem cells 
must be subject to independent review, approval, and ongoing monitoring 
by human subjects research oversight bodies.‖184 Further, the ISSCR reite-
rates the need for independent review and informed consent to maximize 
respect for the voluntary nature of any subject‘s participation in clinical 
  
179 HERBERT GOTTWEIS ET AL., THE GLOBAL POLITICS OF HUMAN EMBRYONIC STEM CELL 
SCIENCE, 189–90 (2009) (investigating the interaction between national regulatory formation 
and the global bio-politics of regenerative medicine and human embryonic stem cell 
science). 
180 Insoo Hyun et al., Commentary, New ISSCR Guidelines Underscore Major Principles 
for Responsible Translational Stem Cell Research, 3 CELL STEM CELL 607, 609 (2008) (dis-
cussing core principles that should guide the responsible transition of basic stem cell research 
into appropriate clinical applications). 
181 Id. 
182 Hyun et al., supra note 180, at 609. 
183 Guidelines for the Clinical Translation of Stem Cells, supra note 21. 
184 Id. 
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trials.185 Fortunately, portions of the ISSCR guidelines are uniquely suited 
for adoption into treaty language. 
2.  Model treaties  
The international community has come together to address many 
human rights and public health issues through treaties. For instance, in 
2005, the WHO successfully implemented International Health Regulations 
to enhance the international community‘s ability to prevent and respond to 
acute public health risks.186 The International Health Regulations are legally 
binding on all 194 WHO Member States, including the United States.187 
In June 1997, the WHO gained endorsements from the American 
Public Health Association and the 10th World Conference on Tobacco and 
Health to develop a treaty in response to the globalization of the tobacco 
epidemic.188 On May 21, 2003, the World Health Assembly adopted the 
WHO Framework Convention on Tobacco Control (FCTC), which entered 
into force on February 27, 2005.189 In 2009, the FCTC published guidelines 
on: (i) protecting public health policies with respect to tobacco control; (ii) 
protecting individuals from exposure to tobacco smoke; (iii) establishing 
packaging and labeling of tobacco products regulations; and (iv) banning 
tobacco advertising, promotion, and sponsorship.190 
Another treaty, the Convention on the Rights of Persons with Dis-
abilities (CRPD), entered into force in May 2008 and serves as a successful 
model for international action.191 To date, 147 countries have signed the 
CRPD and 97 have ratified it.
192
 The CRPD treaty requires that States 
―adopt all appropriate legislation‖ to ―ensure and promote the full realiza-
  
185 Id. 
186 See What are the International Health Regulations?, WHO, http://www.who.int/ 
features/qa/39/en/index.html (last updated Apr. 10, 2008). 
187 WHO, Revision of the International Health Regulations, WHO Doc. WHA58.3 (May 
23, 2005). 
188 See Maureen Bezuhly et al., International Health Law, 32 INT‘L L. 539, 550 (1998) 
(discussing how WHO endeavored to build support for the development of a framework 
convention on tobacco and how the U.N. focal point on tobacco, established and streng-
thened contacts with governments, nongovernmental organizations, and over thirty U.N. 
organizations to garner international support). 
189 WHO Framework Convention on Tobacco Control, 42 I.L.M. 518 (May 21, 2003). 
190 WHO FRAMEWORK CONVENTION ON TOBACCO CONTROL, GUIDELINES FOR 
IMPLEMENTATION: ARTICLE 5.3; ARTICLE 8; ARTICLE 11; ARTICLE 13 at 1 (2009) [hereinafter 
FCTC GUIDELINES FOR IMPLEMENTATION]. 
191 Convention on the Rights of Persons with Disabilities art. 1, G.A. Res, 61/106, U.N. 
Doc. A/RES/61/106 (Jan. 24, 2006). 
192 U.N. Enable, U.N., http://www.un.org/disabilities/ (follow link to ―Signatories & Ratifi-
cations‖) (last visited Mar. 26, 2011).  
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tion of all human rights‖ for people with disabilities.193 Additionally, States 
must modify or abolish all existing ―laws, regulations, customs and practic-
es that constitute discrimination‖ against people with disabilities.194 The 
official United Nations interpretation of the CRPD requires States to include 
explicit protections in their legal instruments, both in national laws and con-
stitutions.195 And, according to the United Nations, the CRPD marks a ―pa-
radigm shift‖ in international attitudes and approaches to persons with dis-
abilities.196  
An additional area of successful international action is demonstrat-
ed by the international regulation of child labor.197 In 1999, the International 
Labour Organization (ILO), a tripartite U.N. agency that brings together 
governments, employers, and workers to promote international regulations, 
adopted the Worst Forms of Child Labour Convention as ILO Convention 
No. 182.198 One hundred and seventy-three countries, including the United 
States, have ratified the ILO Convention.199 The ILO Convention imparts 
the need to ―reach out to the children at special risk‖ and prevent children 
from engaging in the worst forms of child labor.200 The ILO Convention 
further asserts that the ―best interests of the child shall be a primary consid-
eration.‖201  
On the broader subject of protecting individual interests, medical 
treatment should not be classified as an available treatment unless there is 
general recognition among experts, founded on substantial evidence, that 
  
193 Convention on the Rights of Persons with Disabilities, supra note 191, art. 4, cl. 1. 
194 Id. 
195 ANDREW BYRNES ET AL., FROM EXCLUSION TO EQUALITY: HANDBOOK FOR 
PARLIAMENTARIANS ON THE CONVENTION FOR THE RIGHTS OF PEOPLE WITH DISABILITIES AND 
ITS OPTIONAL PROTOCOL III (2007). 
196 Joint Statement of Commitment to the Convention on the Rights of Persons with Dis-
abilities, United Nations Inter-Agency Support Group for the Convention on the Rights of 
Persons with Disabilities (available online at www.un.org/disabilities/documents/iasg/soc. 
pdf). 
197 See Jonathan P. Hiatt & Deborah Greenfield, The Importance of Core Labor Rights in 
World Development, 26 MICH. J. INT‘L L. 39, 41 (2004) (articulating how labor and trade 
linkage provisions respect domestic labor law as well as core labor rights). 
198 See Mission and Objectives, ILO, http://www.ilo.org/global/about-the-ilo/mission-and-
objectives/lang--en/index.htm; see also ILOLEX Database of Int’l Labour Standards, Ratifi-
cation by Country or by Convention, ILO, http://www.ilo.org/ilolex/english/newratframeE. 
htm. 
199 ILOLEX Database of Int’l Labour Standards, supra note 198. 
200 ILO Convention (No. 182) Concerning the Prohibition and Immediate Action for the 
Elimination of the Worst Forms of Child Labour, art. 7(2)(d), June 17, 1999, S. Treaty Doc. 
No. 106-5 (1999), 2133 U.N.T.S. 151 [hereinafter Worst Forms of Child Labour Conven-
tion]. 
201 Id. art. 7(2)(d). 
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the treatment, in fact, produces the results claimed under prescribed condi-
tions.202 As such, hESC-based therapy must be treated as experimental and 
conducted only in clinical trials until accepted as standard medical treat-
ment.203 Once hESC-based therapies are categorized as research instead of 
treatment, the informed consent requirements of the Nuremberg Code and 
Declaration of Helsinki must apply. Additionally, Article 16 of the Oviedo 
Convention must be codified in international regulations to harmonize stan-
dards in determining when it is permissible to conduct research on human 
subjects.204 The principles from these treaties, taken with the ISSCR guide-
lines, form the basis to develop a comprehensive international regulatory 
framework.  
3.  Using the ISSCR guidelines and model treaties to create an interna-
tional framework for regulating hESC-based therapy 
To address vulnerable populations lured by deceptive and mislead-
ing advertising, the international community should adopt key principles 
from the WHO FCTC to ban all misleading advertising promoting hESC-
based therapies.205 Certainly, it is inevitable that spotlighting this issue in-
ternationally will bring about heightened public awareness.  
Proposed hESC regulations must also address the lack of interna-
tional regulations206 by requiring each ratifying State to take legislative ac-
tion, or promote existing laws, to address clinics offering unregulated 
hESC-based therapies.207  
The draft hESC regulations (Draft Treaty), attached to this Note as 
Appendix A, is based on, and adapted from, the ISSCR guidelines and the 
previously discussed treaties.208 The Draft Treaty, if implemented, would 
require ratifying States to: (i) declare all hESC-based therapies as experi-
  
202 Rutherford, supra note 93. 
203 See generally INDIAN DEP‘T OF BIOTECHNOLOGY & INDIAN COUNCIL OF MED. RESEARCH, 
GUIDELINES FOR STEM CELL RESEARCH AND THERAPY (2007). Despite India‘s guidelines, 
there are still reports that unregulated hESC therapies are offered at clinics in India. See 
Kiatpongsan & Sipp, supra note 17.  
204 Oviedo Convention, supra note 103. 
205 See WHO Framework Convention on Tobacco Control, supra note 189.  
206 Kiatpongsan & Sipp, supra note 17. 
207 See, e.g., WHO, Revision of the International Health Regulations, supra note 187; 
WHO Framework Convention on Tobacco Control, supra note 189; Convention on the 
Rights of Persons with Disabilities, supra note 191; and Worst Forms of Child Labour Con-
vention, supra note 200.  
208 See Guidelines for the Clinical Translation of Stem Cells, supra note 21; see also Ovie-
do Convention, supra note 103; WHO, Revision of the International Health Regulations, 
supra note 187; WHO Framework Convention on Tobacco Control, supra note 189; Conven-
tion on the Rights of Persons with Disabilities, supra note 191; and Worst Forms of Child 
Labour Convention, supra note 200.  
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mental and allowable only in a clinical trial setting—until accepted as rou-
tine medical practice; (ii) promote public awareness regarding the medical 
efficacy and safety of hESC-based therapies; (iii) ban all misleading adver-
tising promoting hESC-based therapies; and (iv) take legislative action to 
ensure criminal and civil liability for clinics offering unregulated hESC-
based therapies. 
And, while the attached Draft Treaty represents another key step 
towards regulating hESC-based therapies, there are potential roadblocks and 
objections to overcome.  
4.  Roadblocks to achieving international regulation 
Because 13 different countries already approve the ISSCR guide-
lines, garnering further consensus through United Nations action is quite 
promising.209 At the same time, treaties can take a very long time to pass 
and presumably longer yet to implement. For example, it took 21 years from 
the inception of the CRPD to when it became international law.210 While 
reaching consensus may be a time consuming process, the impact of global 
consensus can be instrumental in changing State practices. For instance, 
shortly after the passage of the Worst Forms of Child Labour Convention, 
Indonesia became one of the first countries to take action to end the em-
ployment of 1,900 children working on dangerous fishing platforms.211 
Thus, criticizing the lawmaking process as slow is not sufficient reasoning 
for abandoning a solution altogether. 
Of greater concern than the speed of implementation is the fact that 
the countries most likely to enter into a treaty are not likely to be the same 
countries that allow clinics to exploit vulnerable patient populations. While 
this is a relevant criticism, the very fact that international law condemns 
such practices will raise public awareness and help mitigate instances of 
  
209 Hyun et al., supra note 180, at 609. 
210 Arthur O‘Reilly, A UN Convention on the Rights of Persons with Disabilities: the Next 
Steps, 17 DISABILITY WORLD (2003), http://www.disabilityworld.org/01-03_03/news/ 
unconvention.shtml. 
211 Press Release, Int‘l. Labour Org., ILO Worst Forms of Child Labour Convention Comes 
into Force, (Nov. 17, 2000) (available online at http://www.ilo.org/global/About_the_ILO/ 
Media_and_public_information/Press_releases/lang--en/WCMS_007917/index.htm). The 
ILO highlights several other examples of the impact of the Worst Forms of Child Labour 
Convention. Id. Examples in the ILO‘s press release have included: (1) the establishment of 
child labour training courses for all officials of the education department in Bangladesh; (2) 
the development of a National Plan of Action for the eradication of the worst forms of child 
labour in South Africa; (3) large-scale projects on commercial agriculture and fireworks 
production; and (4) the development of large-scale projects on domestic service, child prosti-
tution, mining and child soldiers. Id. 
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unsuspecting stem cell tourists traveling abroad to receive putative thera-
pies.  
The international community can infer from the FCTC‘s findings 
that exposure to tobacco advertisements increases the use of tobacco, and 
analogously, exposure to hESC-based therapy advertisements increases the 
occurrence of stem cell tourism.212 The FCTC chose to reduce the use of 
tobacco by advocating for a comprehensive ban on tobacco advertising, 
promotion, and sponsorship.213 Here, by increasing public awareness about 
putative hESC-based therapies and decreasing the means of advertisement, 
promotion, and sponsorship, the rate of stem cell tourism for these types of 
therapies should decrease. 
Also, it may be unfair to presume that all individuals and clinics of-
fering putative hESC treatments have only financial or self-serving inter-
ests—some may truly believe that the treatments work. However, without 
clinical efficacy, mere belief that a treatment is effective, without valid 
proof, is not sufficient reasoning to expose patients to undue risk—
regardless of the size of economic or career impact. Further, this violates the 
WMA‘s medical ethics guidelines to ―act in the patient‘s best interest when 
providing medical care.‖214 
Lastly, critics will argue that hESC-based therapy regulations will 
limit the freedom of choice for global citizens in the selection of medical 
care. However, this is not a sufficient reason to jeopardize the health and 
financial well-being of vulnerable patient populations or expose the public 
to unstable biological hazards. The ability and right of legislatures to protect 
the health, safety, and welfare of the public has been upheld time and time 
again.215  
IV. CONCLUSION 
Unregulated hESC-based therapies have transcended the national 
stage into a global forum in need of international regulation. Several model 
declarations and treaties serve as effective examples to develop and imple-
  
212 FCTC GUIDELINES FOR IMPLEMENTATION, supra note 190, at 49–59. 
213 Id. 
214 WMA INT‘L CODE OF MED. ETHICS, supra note 90. 
215 See, e.g., Dent v. West Virginia, 129 U.S. 114 (1889) (examining the scope of the 
states‘ discretion to regulate the practice of medical care); Lawton v. Steele, 152 U.S. 133 
(1892) (outlining the power of the state to abate nuisances under the police powers); Austin 
v. Tennessee, 179 U.S. 343 (1900) (upholding Tennessee‘s limits on the sale of cigarettes); 
Compagnie Francaise de Navigation a Vapeur v. State Board of Health, 186 U.S. 380 (1902) 
(upholding the state power to quarantine interstate commercial goods to protect the public); 
Jacobson v. Massachusetts, 197 U.S. 11 (1905) (upholding the constitutionality of Massa-
chusetts mandatory vaccination laws and declaring that persons are subjected to restraints 
and burdens in order to secure the general comfort, health, and prosperity of the State).  
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ment key portions of the ISSCR guidelines to protect human dignity and 
public health and promote the obligation of a physician to do no harm.  
Action by the U.N. Security Council is one immediate solution to 
require States to mandate international regulation of hESC-based therapies. 
Additionally, the attached Draft Treaty is a step in the right direction to pro-
tect all man-kind.216 All three solutions discussed can promote global best 
practices in—and accelerate the promise of—translational stem cell thera-
pies, while protecting the public health. If any of the solutions are imple-
mented, they will, at a minimum, reduce the number of unregulated clinics 
offering putative and potentially harmful hESC-based therapies.  
The international community has come together to address many 
human rights and public health issues in the past. Now is the time for the 
United Nations to address clinics offering unsafe hESC-based therapies and 
prompt the collaboration of the international community to advance science 
while ensuring human dignity. 
Just as science continues to quickly evolve, there are new regulatory 
pathways to explore. Further research should apply lessons learned from 
trade regulations and explore ways that international trade and commerce 
laws can reward model stem cell clinics and penalize rogue clinics that vi-
olate international regulations. Specific areas to advance include: streng-
thening enforcement mechanisms, enhancing border control techniques, 
establishing an international accreditation process, and imposing sanctions 
on countries that detract from the promise of hESC-based therapies. 
APPENDIX A 
DRAFT LANGUAGE OF A MODEL HESC TREATY217 
 
WHO Framework Convention on Human Embryonic Stem Cell-Based 
Therapies 
 
Preamble 
 
The Parties to this Convention, 
 
Determined to give priority to their right to protect public health, 
  
216 See infra Appendix A. 
217 Author of this Note adopted and tailored language from the following guidelines and 
treaties: Guidelines for the Clinical Translation of Stem Cells, supra note 21; Oviedo Con-
vention, supra note 103; WHO, Revision of the International Health Regulations, supra note 
187; WHO Framework Convention on Tobacco Control, supra note 189; Convention on the 
Rights of Persons with Disabilities, supra note 191; and Worst Forms of Child Labour Con-
vention, supra note 200.  
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Seriously concerned about the potential adverse impacts of human 
embryonic stem cell (hESC) based treatments offered without peer-
reviewed safety and efficacy data from clinical trials, 
 
Recognizing that cooperative action is necessary to protect patients 
from receiving unproven hESC-based therapies to mitigate the potential of 
suffering adverse health outcomes as a result, 
 
Conscious of the valuable work being conducted by many States on 
hESC transplantation regulation and commending the leadership of the 
World Health Organization as well as the efforts of other organizations and 
bodies of the United Nations and other international and regional intergo-
vernmental organizations in developing measures on regulating the clinical 
application of hESCs, 
 
Recalling Article 12 of the International Covenant on Economic, 
Social and Cultural Rights, adopted by the United Nations General Assem-
bly on 16 December 1966, which states that it is the right of everyone to the 
enjoyment of the highest attainable standard of physical and mental health, 
 
Recalling also the preamble to the Constitution of the World Health 
Organization, which states that the enjoyment of the highest attainable stan-
dard of health is one of the fundamental rights of every human being with-
out distinction of race, religion, political belief, economic or social condi-
tion, 
 
Determined to promote clinical translation of hESC-based therapies 
based on current and relevant scientific, technical and economic considera-
tions, 
 
Conscious that the misuse of biology and medicine may lead to acts 
endangering human dignity, 
 
Stressing the need for international co-operation so that all humani-
ty may enjoy the benefits of biology and medicine, 
 
Resolving to take measures as necessary to safeguard human dignity 
and the fundamental rights and freedoms of the individual with regard to the 
application of biology and medicine, 
 
Have agreed, as follows: 
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Article 1 
 
Allowing hESC-based Therapies in Approved Clinical Trials 
 
The Parties undertake to develop and promote national research and 
to coordinate research programs at the regional and international levels in 
the field of hESC clinical applications. Each party shall only conduct hESC 
research on human subjects when: 
 
(a) there is no alternative of comparable effectiveness to research     
  on humans; 
(b) the risks which may be incurred by that person are not dispro portionate 
  to the potential benefits of the research; 
(c) the research project has been approved by a competent institutional   
  review board or other regulatory body after independent examination  
  of its scientific merit, including assessment of the importance of the   
  aim of the research, and multidisciplinary review of its ethical ability; 
(d) the persons undergoing research have been informed of their rights and 
  the safeguards prescribed by law for their protection; and 
(e) the persons undergoing research have expressly given free and in-   
  formed consent that is then documented. 
 
Article 2 
 
Education, Communication, and Public Awareness 
 
Each party shall promote and strengthen public awareness of hESC-
based therapies, using all communication tools, as appropriate. Towards this 
end, each Party shall adopt and implement effective legislative, executive, 
administrative or other measures to promote: 
 
(a) broad access to effective and comprehensive educational and public   
  awareness programs on the health risks of receiving unregulated hESC-
  based therapies; 
(b) public access, in accordance with national law, to a wide range of in- 
  formation on hESC-based therapies; and 
(c) awareness and participation of public and private agencies and non-  
  governmental organizations in developing and implementing intersec- 
  toral programs and strategies for hESC-based therapy regulation. 
 
Article 3 
 
Advertising, Promotion, and Sponsorship of hESC-based Therapies 
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1. Parties recognize that a comprehensive ban on advertising, 
promoting, and sponsorship of unregulated hESC-based therapies would 
reduce the availability of such unregulated hESC-based therapies to vulner-
able patient populations. 
 
2. Each Party shall, in accordance with its constitution or constitu-
tional principles, undertake a comprehensive ban on all unregulated hESC-
based therapy advertising, promotion, and sponsorship. This shall include a 
comprehensive ban on cross-border advertising, promotion, and sponsorship 
origination from its territory. In this respect, within the period of five years 
after entry into force of this Convention for that Party, each Party shall un-
dertake appropriate legislative, executive, administrative or other measure 
to ban such advertisements, promotions, and sponsorships. 
 
Article 4 
 
Protection from Exposure to Unregulated hESC-based Therapies 
 
1. Parties recognize that scientific evidence has not established the 
safety and efficacy of hESC-based therapies as standard medical treatment 
and until such data is available, any proposed hESC-based therapy must be 
conducted in a clinical trial setting that has been approved by an institution-
al review board. 
 
2. Each Party shall adopt and implement in areas of existing na-
tional jurisdiction as determined by national law, and actively promote at 
other jurisdictional levels, the adoption and implementation of effective 
legislative, executive, administrative and other measures, providing for pro-
tection from unregulated hESC-based therapies. 
 
3. For the purpose of this Convention, the parties shall take legis-
lative action or promote existing laws to deal with criminal and civil liabili-
ty, including allowing compensation for individuals injured by unregulated 
hESC-based therapies where appropriate. 
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    (© 2006 Terese Winslow)  
  
218 U.S. DEP‘T OF HEALTH AND HUMAN SERVICES, REGENERATIVE MEDICINE, supra note 6, 
at 2 fig. 1.2.  
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219 U.S. DEP‘T OF HEALTH AND HUMAN SERVICES, REGENERATIVE MEDICINE, supra note 6, 
at 3 fig. 1.3.  
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220 U.S. DEP‘T OF HEALTH AND HUMAN SERVICES, REGENERATIVE MEDICINE, supra note 6, 
at 1 fig. 1.1.  
